WO2002090505A2 - Multiple sequencible and ligatible structures for genomic analysis - Google Patents

Multiple sequencible and ligatible structures for genomic analysis Download PDF

Info

Publication number
WO2002090505A2
WO2002090505A2 PCT/US2002/014431 US0214431W WO02090505A2 WO 2002090505 A2 WO2002090505 A2 WO 2002090505A2 US 0214431 W US0214431 W US 0214431W WO 02090505 A2 WO02090505 A2 WO 02090505A2
Authority
WO
WIPO (PCT)
Prior art keywords
target site
pcr
dna
primer
sequence
Prior art date
Application number
PCT/US2002/014431
Other languages
French (fr)
Other versions
WO2002090505A3 (en
Inventor
Xiangning Chen
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Priority to US10/476,970 priority Critical patent/US7262030B2/en
Priority to AU2002305436A priority patent/AU2002305436A1/en
Publication of WO2002090505A2 publication Critical patent/WO2002090505A2/en
Publication of WO2002090505A3 publication Critical patent/WO2002090505A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6853Nucleic acid amplification reactions using modified primers or templates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification

Definitions

  • the invention generally relates to single nucleotide polymorphism (SNP) genotyping.
  • SNP single nucleotide polymorphism
  • the invention provides a method for SNP genotyping based on a nested PCR design that creates structures directly suitable for both DNA sequencing and ligation reactions.
  • SNPs entered the central arena of genetics due to their abundance (Collins et al, 1997; Sachidanandam et al, 2001), stability (Sachidanandam et al, 2001) and the relative ease (Kwok 2000; Shi 2001; Syvanen 2002) with which they are genotyped.
  • the targets of SNP genotyping are normally small pieces of DNA, ranging from 150-300 base pairs.
  • the average SNP density in the human genome appears to be greater than 1 SNP/KB. This high density provides a tool to analyze genomic structure at very high resolution, and to establish a direct correlation between genetic coding variation and biological function.
  • SNP genotyping is generally easier than microsatellite genotyping, and despite the rapid and significant advances in SNP genotyping technology in the last few years, major issues remain unsolved. Whereas only a few years ago, the main concern was the need to have a large number of SNPs available, currently the most urgent issues are increasing throughput and decreasing cost. For example, for large scale applications as projected by Kruglyak (1999) and Long (1999), a reasonable cost would be ⁇ $0.10/genotype, or else large-scale projects will become prohibitively expensive. To fulfill the goals of understanding the genetics of complex traits and common diseases, cost- effective and higher throughput methodology in SNP genotyping is essential.
  • genotyping protocols typically have three components: target amplification, allelic discrimination and product detection and identification. They are normally executed sequentially, but can be processed in a single step reaction, depending on the means which are used for allele discrimination and signal detection. Such single step procedures are well- suited to automation, but are not necessarily effective in terms of cost and throughput.
  • PCR is the dominant procedure utilized for target amplification. As is widely known, a PCR can readily amplify targets present in lower copy number by a factor of 10 8 or more.
  • all SNP genotyping technologies currently available are based on mechanisms involving one or more of the following: DNA polymerase, hybridization and DNA ligase.
  • DNA polymerase methods include single base extension (SBE) (Armstrong, 2000; Barta 2001; Bray 2001; Cai 2001; Chen 1997; Chem 1999; Chen 1998; Chen 1997; Chen 1997; Fan 2000; Lindblad-Toh 2000;Nikiforov 1994; Pastinen 1996; Pastinen 2000; Ross, 1998; Sauer 2000; Syvanen 1999; Ye 2001), de novo sequencing including pyrosequencing (Nordstrom 2000; Ronaghi 2001), allele-specific
  • PCR and extension (Germer 1999; Myakishev 2001; Pastinen 2000), and structure-specific cleavage (Fors 2000).
  • SBE is the most widely used and has been adapted for many different detection platforms.
  • Hybridization is also widely used in several different forms, including dynamic hybridization (Prince 2001), and is the primary method currently used in all microarray detection formats.
  • DNA ligase methods are based on the ability of DNA ligase to join the ends of two oligonucleotides annealed next to each other on a template (Tong 2000; Tongl999).
  • Two oligonucleotides can be designed to anneal to both sides of a SNP site, and by detecting the formation of ligation product, the genotype of a target can be inferred (Chen 1998; Delahunty 1996; Gerry 1999; Iannone 2000). Once a target DNA sequence has been amplified and the allelic variants discriminated, the next step in a generic genotyping protocol is to detect and identify the allele specific products.
  • Detection mechanisms vary greatly, from simple fluorescence intensity (Armstrong 2000; Cai 2000;Chen 1998; Chen 1997; Delahunty 1996; Dubertret 2001; Fan 2000; Fergusoon 2000; Fors 2000; Germer 1999; Germer 2000; Gerry 1999; lannone 2000; Lindblad-Toh 2000; Lindroos 2001; Marras 1999; Medintz 2001; Myakishev 2001; Nikiforov 1994; Pastinen 1997; Pastinen 2000; Prince 2001; Syvanen 1999; Ye 2001) to very precise mass (Bray 2001; Ross 1998; Sauer 2000) or electric charge (Gilles 1999; Woolley 2000) measurement.
  • the detection mechanisms roughly fall into two categories: homogeneous and solid phase mediated detection.
  • the present invention provides a methodology for high-throughput SNP genotyping that is highly cost effective.
  • This novel approach makes use of the high throughput capacity of DNA sequencers for SNP genotyping and is based on a nested PCR design that creates a series of ordered "structures" in parallel and exploits them for SNP genotyping assays.
  • the invention thus provides novel genotyping technologies that significantly increase throughput, reduce cost and are accessible for most researchers, leading to significant improvements in genotyping technology. While typical SNP genotyping approaches currently available score ⁇ 10 SNPs simultaneously, the methods of the present invention increase the number to about 50-100 with obvious advantages for throughput and cost.
  • the present invention provides a method of producing hybrid DNA with a single strand overhang that includes a target sequence.
  • the steps of the method include: obtaining a first primer which hybridizes to a 5' strand of a strand of deoxyribonucleic acid (DNA), a second primer which hybridizes to a 3' strand of the strand of DNA, and a third primer which hydridizes to said 3' strand of DNA; producing by nested polymerase chain reaction (PCR) using the first primer, the second primer, and the third primer, an outer amplicon which includes a target sequence and an inner amplicon which excludes the target sequence; forming at least one of the following: a ligatable structure which includes a 3'-5' sequence which excludes the target sequence hybridized to a 5'-3' sequence which includes the target sequence, and a sequencible structure which includes a 5 '-3' sequence which excludes the target sequence hybridized to a 3'-5' sequence which includes the target sequence; sequencing the sequencible structure(s) and ligating the ligatible structure(s) with a labeled oli
  • the invention also provides a method of genotyping the deoxyribonucleic acid (DNA) of an individual by analyzing at least on target sequence in the DNA.
  • the steps of the method include: obtaining a first primer which hybridizes to a 5' strand of a strand of said DNA, a second primer which hybridizes to a 3' strand of the strand of DNA, and a third primer which hydridizes to the 3' strand of DNA; producing by nested polymerase chain reaction (PCR) using the first primer, the second primer, and the third primer, an outer amplicon which includes said target sequence and an inner amplicon which excludes the target sequence; and forming at least one of the following: a ligatable structure which includes a 3'-5' sequence which excludes the target sequence hybridized to a 5'-3' sequence which includes the target sequence, and a sequencible structure which includes a 5'-3' sequence which excludes the target sequence hybridized to a 3'-5' sequence which includes the target sequence; sequencing the
  • the forming step of the method may form both the ligatible structure and the sequencible structure.
  • the target sequence(s) may include a single nucleotide polymorphism.
  • the sequencible structure may be sequenced by a technique such as dideoxy sequencing, pyrosequencing, and single base extension.
  • a plurality of target sequences is analyzed; ii) the step of forming forms an ordered series of sequencible structures; iii) the step of sequencing produces an ordered series of sequencing products of varying, non- overlapping length; and iv) the step of analyzing is carried out by electrophoresing the ordered series of sequencing products in a single channel of said DNA sequencer.
  • the step of sequencing is carried out by single base extension (SBE).
  • the step of sequencing is carried out by a dideoxy sequencing reaction utilizing a ratio of dNTPs to ddNTPs that is lower than that which is typically used in order to produce a short sequence reading.
  • the labeled oligonucleotide is fluorescently labeled.
  • a plurality of target sequences is analyzed; ii) the labeled oligonucleotides are degenerate; iii) the ligation products are of varying, non- overlapping lengths; and iv) the step of analyzing is carried out by electrophoresing a plurality of ligation products in a single channel of said DNA sequencer.
  • the present invention also provides a method for analyzing at least one target site in a DNA molecule.
  • the method includes the steps of:l) amplifying the target site(s) by nested PCR; (The nested PCR is carried out using inner and outer PCR primer pairs, wherein the outer PCR primer pair forms a first PCR product which contains a target site, and the inner PCR primer pair forms a second PCR product which contains a portion of the first PCR product but does not contain the target site); 2) denaturing the first and said second PCR products to form ssDNA sequences, 3) reannealing the ss DNA sequences to form a sequencible hybrid DNA molecule and a ligatible hybrid DNA molecule, 4) performing sequencing reactions with said sequencible hybrid DNA molecule and ligation reactions with said ligatible hybrid DNA molecule, and 5) determining the characteristics of the target sequence by analyzing results obtained in the performing step.
  • the target site(s) may be SNP polymorphism sites.
  • the inner and outer primer pairs may comprise a sequence tag, which in turn may comprises a restriction enzyme recognition site.
  • the step of amplifying may be carried out using a low concentration of primers, and may further comprising a second step of amplification using secondary primers for amplification of the sequence tags.
  • one or several target sites may be analyzed.
  • the step of amplifying may be carried out in a single multiplex PCR reaction, or in multiple independent PCR reactions, and the results may be analyzed by a DNA sequencer.
  • the invention also provides inner and outer PCR primer pairs for the amplification of a target sequence in a DNA molecule, wherein the outer PCR primer pair forms a first PCR product which contains the target sequence, and the inner PCR primer pair forms a second PCR product which contains a portion of the first PCR product but does not contain said target sequence.
  • the target sequence may be an SNP polymorphism site.
  • the primer pairs may comprise a sequence tag.
  • the present invention also provides a kit for amplification of at least one target sequence in a DNA molecule.
  • the kit includes inner and outer PCR primer pairs for the amplification of the target sequence.
  • the outer primer pair amplifies a portion of the DNA molecule which includes the target sequence, and the inner primer pair amplifies part of the same portion of the DNA molecule that is amplified by the outer primer pair, but excludes the target sequence.
  • the inner and outer PCR primer pairs may comprise sequence tags.
  • the kit may further comprise secondary primers for the amplification of the sequence tags.
  • the present invention also provides a dideoxy DNA sequencing kit for producing short chain termination fragments.
  • the kit includes dNTPs and ddNTPs which are present in a low dNTP:ddNTP ratio.
  • FIG. 1 A schematic drawing illustrates a nested PCR design that would create both a sequencible and a ligatible structure.
  • the reaction uses two primer sets (inner and outer). PI, forward outer and forward inner primer; P2, reverse inner primer; P3, reverse outer primer.
  • PI forward outer and forward inner primer
  • P2, reverse inner primer P3, reverse outer primer.
  • Figure 2A and B A, a multiplex PCR scheme that amplifies three target sites.
  • Two primer sets inner and outer are used for the amplification of each target site.
  • the target sites are represented by "x". All primers contain two domains, a common domain and a target specific domain.
  • the target specific domains indicated by arrows, have sequences unique to the targets, whereas the common domains are not target specific.
  • B close-up view of common domain of inner primer shows restriction sites incorporated into the sequence of the domain.
  • the sequence SEQ ID NO.
  • Figure 4A and B A. Depiction of nested PCR primer design.
  • the sequence SEQ ID NO.
  • FIG. 3 represents 494 nucleotides from human chromosome 6. Nucleotides corresponding to primer pairs are shaded with gray, and arrows indicate primer orientation. Arrow indicates site of polymorphism.
  • the sequence which was generated by ABI 377 sequencer is shown in italics, and is also depicted in Figure 4B (SEQ ID NO. 4). Two samples were shown in Figure 4B. The upper panel was a heterozygote (C/T), at base position 24, as pointed by the arrow, both bases ⁇ and T) were identified. The lower panel was a homozygote (T/T), at the indicated position only the T base was identified.
  • SNP single nucleotide polymorphism
  • Figure 5 SBE genotyping using sequencible structures from nPCR products amplified by Pfu DNA polymerases. Nested PCR primers were designed for an SNP marker from human chromosome 6. The inner product size is 189 bp, its 3' end is positioned immediately upstream to the polymorphic site when it forms sequencible structures. PCRs were performed with DNA samples of known genotypes. After PCRs the outer and inner products were purified and denatured together to form sequencible structures. SBE reactions were performed and products analyzed in ABI 377 Sequencer using Genescan.
  • the upper panel is a homozygous A/A where an SBE product of 190 bp is found (arrow). Products of the same size are found in the heterozygous (middle panel) and the other homozygous (lower panel).
  • the peaks after the dye front are ROX500 size makers (35, 50, 75, 100, 139, 150, 160, 200, 250 bp respectively).
  • Figure 6 An example illustrates a short sequence read with a specially assembled sequencing mixture that has a different ddNTPs/dNTPs ratio.
  • the components used for the example were the following: 1.75 ⁇ M of -21 M13 primer, 300 ng of pGEM, 60 ⁇ M of each dNTPs, 2.5 ⁇ M of R6G-acyclo-ATP, 12 ⁇ M of ROX-acyclo-CTP, 10 ⁇ M of BODIPY- Fluorescein-acyclo-GTP, 25 ⁇ M of TAMRA-acyclo-UTP, 1 unit of AcycloPol DNA polymerase and lx AcycloPol reaction buffer.
  • the thermal cycling conditions were 96 °C for 3 min., followed by 25 cycles of 96 °C for 1 min., 50 °C for 15 sec. and 60 °C for 4 min.
  • Figure 7 The thermal cycling conditions were 96 °C for 3 min., followed by 25 cycles of 96 °C for 1 min., 50 °C for 15 sec. and 60 °C for 4 min.
  • Lane 1 was a 4x multiplex PCR with simple PCR design
  • Lane 2 was the same 4 amplicons but with the two domain design
  • Lane 3 was the 4x multiplex nPCR with the same amplicons performed in two sequential reactions.
  • the cycling condition was 95 °C for 10 min, followed by 10 cycles of 95 °C for 45 sec, 65 °C for 5 sec, ramping to 55 °C at 0.1 °C/sec and 55 °C for 90 sec.
  • the primers used were different among the three lanes.
  • Lane 1 since it did not have secondary primers, the same primers were used as in first reaction but the concentration increased to 100 nM.
  • Lane 2 used two secondary primers, Ml 3 forward and reverse, each 400 nM.
  • Lane 3 used three primers, Ml 3 forward (600 nM), Ml 3 reverse (400 nM) and the common tag for inner PCR primers (400 nM).
  • the cycling conditions for the second reaction was following: 95 °C for 10 min, followed by 30 cycles of 95 °C for 45 se , 55 °C for 90 sec.
  • the present invention provides methods of high-throughput SNP genotyping that are highly cost-effective.
  • the methods utilize the high-throughput capability of ubiquitous and readily accessible DNA sequencers in order to carry out the SNP analysis. This is possible due to the experimental design of the methods, which are based on nested PCR reactions.
  • the target sites which are analyzed are SNP polymorphism sites.
  • nested PCR is a PCR amplification method that "nests" one PCR reaction within another. Two sets of primers are used: “outer” primers amplify a portion of a DNA strand, and “inner” primers amplify a smaller portion of the same DNA that is located within the larger, outer portion. Thus, two PCR products (amplicons) are produced. One amplicon is smaller than the other and contains a "subset" of the bases contained in the larger, outer amplicon
  • a new design for nested PCR is used.
  • Primers are designed so that the outer amplicon includes a target site (e.g. an SNP polymorphism site) and the inner amplicon excludes the target site.
  • the purpose of the inner PCR in the nested reaction is to synthesize a DNA fragment whose size and position relative to the outer PCR can be precisely controlled.
  • This design concept is illustrated in Figure 1.
  • the inner primer set is composed of primers PI and P2
  • the outer primer set is composed of primers PI and P3.
  • the P1-P3 outer primer set flanks the indicated target site whereas the P1-P2 inner primer pair does not.
  • PCR amplification of the DNA with these primers will produce two amplicons.
  • the larger of the two is the outer amplicon formed by amplification with the P1-P3 pair; this amplicon includes the target site.
  • the smaller of the two amplicons, the inner amplicon contains base pairs which lie within the bounds of the larger outer amplicon (i.e. is "nested" within the larger amplicon) , but does not contain the target site.
  • the ultimate product of the PCR reaction is double strand DNA of two lengths, only one of which (the longer) contains the target site, and the shorter of which contains a subset of the bases contained in the longer strand.
  • the same primer functions as both the outer and inner forward primer.
  • a distinct forward inner primer (“P4", shown in parentheses) might be designed to anneal between PI and P2 and in the orientation of primer PI . Because the shorter amplicon contains bases which are identical to a portion of the longer amplicon, when the ds strands are denatured and allowed to reanneal, some (approximately 50%) of the shorter single strand DNA of the inner amplicon will hybridize with matching portions of the single strand DNA of the outer amplicon.
  • This cross hybridization between the two amplicons creates two different inner-outer "hybrid” structures as depicted in Figure 1.
  • the "ligatible structure" of Figure 1 a 3' overhang will be present, the bases of which originated from the outer amplicon and contain the target site.
  • This structure can be used, for example, for ligation based applications.
  • ligation based applications we mean the smaller amplicon is one of the two or more pieces of DNA that are joined together by a DNA/RNA ligase.
  • the "sequencible structure” of Figure 1 a 5' overhang will be present, the bases of which originated from the outer amplicon and also contain the target site.
  • sequencing applications we mean that the smaller amplicon acts as a sequencing primer to sequence the DNA downstream from it.
  • the sequencing can be only one base in length (i.e. SBE) or in the tens or in the hundreds of bases.
  • SBE single nested PCR reaction followed by denaturation and annealing
  • some (approximately 50%) of the single strand DNA will renature to form the original ds PCR products ("structures same as products” in Figure 1). Years of improvement in primer design and thermocycling conditions have increased the success rate for single target PCR reactions to greater than 90%.
  • a first common domain is a sequence shared by all forward primers and is attached at the 5' end of the target specific domain.
  • a second common domain sequence is shared by all reverse primers and is attached at the 5' end of the target specific domain.
  • the common domain facilitates annealing of different primer sets because the common domain has a higher annealing temperature than the target specific domain.
  • common sequence domains or "sequence tags" as taught by Shuber may be utilized for both inner and/or outer PCR primers.
  • the common sequence tag for the outer PCR primers would help in multiplexing PCR so that amplification would result in the production of equal amounts of product.
  • the common sequence tag for the inner primers also serves to even the levels of PCR products, and in addition may provide restriction sites that can be used to generate precise fragment ends for genotyping reactions such as sequencing and/or ligation reactions.
  • the combination of incorporating special restriction enzyme recognition sequences in such a sequence tag, and the deliberate positioning of the inner PCR primers make it possible to precisely tailor the resulting PCR products for any of a variety of purposes, including but not limited to primer extension, sequencing, ligation, pyrosequencing, structure specific cleavage, and other genotyping reactions.
  • placement of the P2 primer can be anywhere between the target site and the other primer of the inner primer pair, so long as a useful PCR product is produced by PCR amplification of the inner primer pair, and the target site itself is not amplified.
  • the positioning of the P2 primer relative to the target SNP may vary depending on the mechanism of the genotyping reactions. For example, for SBE reactions, the end of the primer should be immediately 5' to the SNP site. For Multi-Target Sequencing (MulTarSeq) reactions, there may be a gap between the end and the target SNP site.
  • MulTarSeq Multi-Target Sequencing
  • the gap may be from about 1 to 50 bases, or more preferably from about 5 to about 20 bases, and most preferably from about 10 to about 15 bases.
  • the desired length of the final product from the amplification of PCR primers containing common sequence tags may also be determined by the presence of a restriction enzyme cleavage site within the tag.
  • the amplification reactions may be carried out in a step-wise fashion using primary and secondary primers.
  • a single PCR is divided into two sequential reactions, the first of which uses the primary primer set and the second of which uses the secondary primer set.
  • the primary primers may be designed to have two domains (target specific and common) as described above.
  • the secondary primer set contains only the common tails from the primary primers.
  • the primary primers are used in only limited but equal amounts, e.g. about 1-5% of the amount for a regular PCR i.e. about 0.1 to about lOOnM.
  • the rationale is that by limiting the amount of primers for each set multiplexed in the reaction, the system is forced to produce limited but equal amounts of products for all amplicons. When the more robust primers are used up (because of the limited amount available) the system will work with the less efficient primers.
  • the purpose of the primary PCR is to amplify enough templates from the genomic DNA to carry out the secondary PCR. Since all primary primers have limited but equal amounts, this forces the primary PCR to produce limited but near equal amounts of templates for the secondary PCR.
  • the secondary primers consisting of only one set for all primary amplicons, is used. In essence this secondary reaction is a single PCR that amplifies multiple templates.
  • the net result of this two-step PCR process is to compensate for differences in efficiency across PCR reactions.
  • the purpose of the inner PCR in the nested reaction is to synthesize a DNA fragment whose size and position relative to the outer PCR can be precisely controlled. By altering the position of the P2 primer relative to PI, and by optionally including sequence tags with restriction sites, it is possible to design longer or shorter PCR fragments.
  • the synthesized fragments can then be used in any of a variety of genotyping reactions, including but not limited to primer extension, sequencing, ligation, pyrosequencing, structure specific cleavage, and the like.
  • the sequencible structure fragments may be used as extension primers in SBE and MulTarSeq reactions.
  • the direct production of sequencible structures by the methods of the present invention thus permits investigators to take advantage of the ready availability of DNA sequencers for the purposes of genotyping.
  • Relatively long primers can be synthesized in this manner in a feasible and much more cost effective way than, as is typically done, by chemical synthesis.
  • the length of such a fragment can range from about 35 to about 1000 bps, and is preferably in the range of about 50 to about 650 bps.
  • To use a standard sequencing reaction to determine the sequences surrounding a polymorphic site it is simply necessary to add an appropriate sequencing mixture without using any sequencing primer, because the sequencible structure provides the free 3' end for the sequence reaction.
  • the procedure illustrated in Figure 1 amplifies a single target and relies on multiplex PCR amplification since more than one pair of primers is used in a single reaction.
  • those of skill in the art will recognize that in many cases it will be desirable to amplify more than one target site at a time.
  • the design of the inner primer pairs for each target site may be such that an ordered series of PCR products of varying lengths is produced, i.e. the sequencible structure formed for each target site differs in length from the sequencible structures formed for each of the other target sites.
  • Figure 2A For example, an ordered series of sequencible structures from about 50 to about 500 bps in length can be designed, thus adding an additional distinguishing feature to each of the amplified target sites. Because of this feature, multiple sets of PCR products can be sequenced in a single reaction providing that the length of sequencing is limited so that their chain termination fragments do not overlap in a sequencing gel. This would allow the sequencing of multiple targets in a single reaction and analysis in a single channel (e.g. a lane or capillary).
  • a single channel e.g. a lane or capillary
  • the length of reading can be adjusted by changing the ratio of ddNTP/dNTP in the reaction mixture.
  • the ratio is typically about 1 : 100, a ratio intended to promote relatively long reads (e.g. about 600-800 bps).
  • a ratio intended to promote relatively long reads e.g. about 600-800 bps.
  • a read of from about 1 to about 50, and preferably from about 1 to about 25 bases would be sufficient, requiring a low ddNTP/dNTP ratio of preferably in the range of about 1 :0 to about 1:10, and more preferably about 1 :0 to about 1:5.
  • the optimal length can be attained by adjusting the ratio, i.e. the ratio may be optimized by methods which are well known to those of skill in the art in order to achieve the desired sequence read length. Precise control of the read allows very high level multiplexes to be carried out (e.g. 100 to 200x).
  • primer design involving placement of the primer and the optional addition of a sequence tag must be carried out.
  • primer design involving placement of the primer and the optional addition of a sequence tag must be carried out.
  • other factors influence primer design and must be taken into account as well.
  • the exact sequence of bases will influence the strength of the hybridization of the primer with its cognate DNA (the sequences of based to which it binds during PCR) and thus must be taken into account when planning PCR amplification protocols; the possibility of primer-dimer formation is taken into account, as is the potential for the formation of secondary structure, etc.
  • the common domains of the inner primers may be designed to include restriction enzyme recognition sites.
  • the restriction enzymes preferred are those that cleave DNA strands downstream from their recognition sites and generate blunt ends products.
  • restriction enzymes that cleave DNA downstream and generate 3' overhangs can also be used.
  • restriction enzymes that cleave DNA downstream and generate 5' overhangs can also be used. Examples of such sites include but are not limited to these enzymes: Mly I, Fst F51, Bpm I, Eco571, Bsg I, Eci I, Bst71 1, Alw26 1, Ksp62 1, BceA I, etc.
  • the other nucleotides in the sequence of a common domain inner primer are selected to balance the melting temperature with that of the common domain of the outer primers.
  • the sequences are selected so that so it will match the melting temperature of the common domain of the inner primer.
  • the generation of the sequencible and ligatible structures of the present invention will be carried out as follows: a PCR amplification reaction is carried out, followed by a restriction with a suitable restriction enzyme if a restriction site was incorporated into a common sequence tag of the inner primers. This is followed by treatment to "clean up" the reaction e.g. with shrimp alkaline phosphatase (SAP) and exonuclease I (Exo I) to degrade excess PCR primers and dNTP left over from the PCR reaction, and to remove the overhanging ends of restriction digestion. (Alternatively, filtration via sephadex gel may also be employed.) After S AP/Exo I digestion, a high temperature denature step is performed.
  • SAP shrimp alkaline phosphatase
  • Exo I exonuclease I
  • This denature step serves two purposes: one is to inactivate both SAP, Exo I and the restriction enzyme; the other is to completely denature double stranded DNA.
  • the four single stranded DNA fragments from the two PCR products will form four kinds of structure. Two of them are the exactly same as the PCR products and are both blunt ended. Two new structures formed between the complementary strands of the large and small PCR products, one of them with a 5' end single stranded, the other one with a 3' end single stranded. The one with a 5' end single stranded provides a free 3 'end for sequencing reaction/primer extension and for ligation, and is referred to as a "sequencible structure".
  • the one with single stranded 3' end provides a free 5' end for ligation, and is referred to as a "ligatible structure".
  • These four structures will have equal concentrations if the quantity of the two PCR products is equal. In this case, the sequencible and ligatible structures will represent about 50% of the reannealed products. This amount is sufficient for both sequencing/primer extension and ligation reactions to make new products.
  • a single target site is analyzed by the methods of the present invention, and the PCR step is carried out by multiplex PCR, i.e. amplification with both the inner and outer primers is carried out in the same reaction.
  • PCR reactions may also be carried out, i.e. the inner and outer PCR reactions are carried out separately.
  • the PCR products from the two reactions may be combined later at some point prior to the renaturation step so that the single strands can reanneal.
  • one or more sites may be amplified together, or each site may be amplified alone, either in a single reaction with both inner and outer primers, or in two reactions, one for the inner and one for the outer primers as described above. Any combination of PCR amplification reactions may be utilized in the practice of the present invention, so long as the procedure results in the production of suitable sequencible and/or ligatible structures.
  • the present invention provides methods which ultimately utilize DNA sequencers or the like to detect the products formed from sequencible and/or ligatible structures created by the present methods.
  • Those of skill in the art will recognize that many suitable techniques exist by which the sequencible products can be produced for analysis by a DNA sequencer. Examples include but are not limited to Sanger-type sequencing reactions, single base extension (SBE), and pyrosequencing.
  • Ligatible structures may be analyzed directly on a DNA sequencer after a labeled oligonucleotide (e.g. fluorescently labeled) is joined to the 5' phosphate of the ligatible structure via a ligation reaction.
  • Single base extension is essentially a sequencing reaction, the difference being that SBE uses only dye-terminators, resulting in the extension of the primer by only a single base.
  • the length and position of the extension primer relative to the polymorphic site may be controlled so that it is possible to create a primer which anneals immediately upstream of a polymorphic site. Then, in a regular SBE reaction, the polymorphic base can be determined by identifying which base(s) is incorporated into the primer. If several target sites are to be analyzed, a set of primers can be designed which, upon amplification of the targeted DNA, produce an ordered set of such sequencible structures of varying, non-overlapping lengths.
  • extension primers from about 50 to over 500 bases can be obtained, it is possible to separate these SBE products in a sequencing gel/capillary.
  • a regular sequencing gel can sequence about 500-800 bases. Therefore, over 100 SNPs can be analyzed in a single channel by loading their corresponding SBE products in one lane/capillary when the extension primers are designed to be positioned, for example, every 4-5 bases apart for a full range of 500-600 bases.
  • the ends of the primers must be precise, i.e.
  • Taq DNA polymerase may in some cases be disadvantageous due to its known extendase activity which interferes with such precision.
  • Those of skill in the art will recognize that a variety of means are available to overcome such a problem.
  • the use of high fidelity polymerases may be employed.
  • Pfu DNA polymerase is a well characterized DNA polymerase that has been shown to have high fidelity of replication (Cline 1996). It is known that Pfu DNA polymerase does not add extra A's at the 3' end (Cline 1996; Hu 1993). Based on a study by Cline et al (Cline 1996) the use of Pfu DNA polymerase gives precise ends of inner PCR products.
  • a second alternative is to use ribonucleotides and/or abasic analogs in the inner primer to control DNA polymerases' end point.
  • Some DNA polymerases do not have reverse transcriptase activity, Pfu and Vent polymerases are examples (Perler 1996). These enzymes can not incorporate any nucleotide when they encounter a ribonucleotide base in a template.
  • Coljee et al recently reported a strategy to create precise overhang at the ends of PCR products by using ribonucleotides (Coljee 2000). The strategy inspired us to use same mechanism to control the ends of inner PCR products.
  • inner primers may be designed to overlap the target SNP site, at the SNP site, instead of using regular deoxyribonucleotide, a ribonucleotide is used.
  • DNA polymerases can use a chimeric oligonucleotide as primer efficiently (Gal 2000; Stump 1999), so the use of chimeric primers would not compromise PCR efficiency.
  • the DNA polymerases will stop one base before the ribonucleotide base in the chimeric inner primers, creating very accurate and precise ends for SBE. It is also possible to create chimeric primers containing several ribonucleotide bases to create several base overhang for the purpose of ligation (Coljee 2000).
  • a nucleotide analog that does not contain the base the abasic analog, has similar effects on DNA polymerase (Gal 2000; Gal 1999) and may be used.
  • restriction enzymes to produce precise 3' ends for sequencible structures.
  • restriction enzymes that cleave DNA strands downstream from their recognition sites, e.g. KSP632 1, Alw26 I, and Bst71 1.
  • a common domain sequence tag
  • the common domains contain restriction enzyme sites which can be positioned so that the 3' extending ends are located just before the polymorphic sites after the tail is cleaved off.
  • the use of a common domain for inner primers could also help to even the amounts among different amplicons when multiplexed.
  • Pyrosequencing is a unique technique that incorporates a sequencing reaction and real time detection together. Since, as in a regular sequencing reaction, pyrosequencing uses
  • the free 3' termini in the sequencible structures can function as extension primers. Since pyrosequencing is a real time system, it is not amenable to the analysis of multiplex reactions. There would thus be no need to use a common tail for the inner PCR primers.
  • the primers for a reaction whose products are destined for analysis by pyrosequencing are designed to accommodate the needs of pyrosequencing, preferably from about 5 to about 8 bases upstream of the target polymorphic site.
  • the ligatible structures produced by the methods of the present invention have a free 5' phosphate.
  • restriction enzyme digestion leaves the 5' phosphate on the ligatible structure.
  • the cleavage site of restriction enzymes used in the inner PCR primer must be immediately down stream of the polymorphic site on the complementary strand.
  • a suitable design of restriction site for ligation assay would not be suitable for SBE reaction, but could be used for MulTarSeq reaction.
  • one advantage of the use of ligation to score a polymorphism is that it can be combined directly with the PCR reaction, resulting in a closed tube assay.
  • DNA fragments have to be labeled with fluorescence dyes.
  • the PCR products are not labeled with any fluorescence dye.
  • the ligatible structures can be detected only if they are ligated to a labeled oligonucleotide, e.g. one that bears a fluorescent label.
  • an oligonucleotide would have a 3' OH group and 5' fluorescence labeling.
  • Current DNA sequencers typically analyze fluorescence with a spectrum between 510-610 nm.
  • fluorescence dyes there are many fluorescence dyes available in this range.
  • the BODIPY series of fluorescent dyes have been shown to minimize emission overlaps between dyes (Metzker 1996).
  • other dyes which may be utilized to carry out this aspect of the invention include but are not limited to FAM, fluorescein, Rl 10, R6G, TAMRA, ROX, Texas red, etc.
  • locus-specific fluorescence- labeled oligos may be utilized.
  • sets of degenerate, fluorescence-labeled oligos are desirable.
  • a common set of four fluorescence dye labeled degenerate oligonucleotides may be utilized. The degeneration of the oligonucleotides is to make them reusable for all potential assays. If an oligonucleotide with a specific sequence is used, it would only work for one particular target.
  • any given sequence would have a concentration of l/4 3 -l/4 4 (i.e. 1/1024-1/4096). If the total concentration for a 7-mer degenerated oligo used in ligation is 1 ⁇ M, the effective concentration for any giving sequence would be greater than 0.2 nM, a concentration at least 100 fold above the detection limit of sequencing gel/capillary.
  • the optimal length of the degenerated oligo and its concentration may vary from experiment to experiment, depending on the level of degeneracy and multiplex used in the reaction.However, the oligo will generally be in the range of about 5- about 20 bps in length with from about 4 to about 19 degenerate bases, and more preferably in the range of about 6 to about 8 bps in length with about 4 to about 6 degenerate bases. Another consideration is the melting temperature for the degenerated oligonucleotide. As is well known to those of skill in the art, the Tm will vary depending on factors such as the GC content, the length of the oligo, and the like. For example, increasing the GC content and/or the length of an oligo increases its Tm.
  • oligonucleotide Increasing the length of oligonucleotide will increase T m , but would decrease the effective concentration for a specific sequence. In addition, other factors such as the ionic strength of the ligation buffer also affect T m significantly.
  • Other considerations involved in oligo design which are well- known to those of skill in the art include the number and position of bases which are degenerated. The number of degenerated bases will have a significant impact on the effective concentration and T m . For example, if 5 degenerated bases are used within a 7 mer, 16 oligos must be synthesized, but if 6 degenerated bases are used, only 4 oligos are necessary.
  • ligase to be employed.
  • a 6-7 mer oligo with a moderate GC content should exhibit a melting temperature between 30-40 °C, a Tm sufficient to perform a cyclic ligation assay.
  • the use of thermal stable DNA ligase would provide an opportunity for multiple cycling of a ligation assay at this temperature, which would compensate for lowered efficiency of the reaction.
  • protocol references, kits, etc. are readily available to facilitate carrying out such manipulations of the DNA. The precise nature of the protocols which are used is not a central feature of the present invention, and any of many suitable means for carrying out the various steps of PCR amplification and detection and analysis of the amplicons may be utilized in the practice of the present invention.
  • the method of detection is capillary electrophoresis.
  • the demand from the human genome project greatly stimulated technology development in DNA sequencing and, in return, improvements in DNA sequencing greatly speeded up the human genome project.
  • capillary DNA sequencers became widely available to researchers in both academe and industry.
  • DNA sequencers are highly sensitive and automated detection systems. They also have a relatively broad detection range, covering at least three orders of magnitude. Their analytical power is better than most signal detection systems currently used for SNP genotyping. Capillary DNA sequencing systems have been proven to deliver ultra high throughput in many DNA sequencing centers around the world.
  • DNA sequencers separate DNA fragments by sizes and colors. In order to separate genotyping products by a sequencer, the products must be different in sizes and or colors. To separate two SBE products, for example, SBE primers must be different in length or the extended bases must be different in color. Otherwise, the two products of same length and same colors would not be distinguished.
  • nPCR primers were designed as described to amplify DNA fragments from six markers of human chromosome 6 and individual nPCR was performed using Taq-Gold DNA polymerases. Clean-up digestion was carried out using shrimp alkaline phosphatase and E. coli exonuclease I (37 °C 1 hour) After the clean-up digestion, a high temperature denaturing (95 °C for 15 min.) was performed and the samples were allowed to cool to room temperature. A sequencing reaction was performed using standard sequencing kits but without sequencing primers. Sequencing reactions were performed either : 1) under standard cyclic sequencing program: 25 cycles of 96 °C forl min., 50 °C for 15 sec.
  • Figure 3 A and B and Figure 4 A and B show the results obtained with the second sequencing reaction protocol.
  • Figures 3 A and 4A show PCR primer positions and orientations, and the expected sequences. Note that in Figure 4, the inner PCR primer is designed in the same orientation as forward, so the sequence reading from a sequencing reaction would be reverse complementary to the sequences highlighted with italics.
  • Figures 3B and 4B show sequencing reads from the ABI 377 sequencer analysis software.
  • the reading length of sequencing reactions is principally determined by the ratio of dNTPs/ddNTPs.
  • long sequence reads are obtained by using a high dNTPs/ddNTPs ratio (-100:1) provided in commercial sequencing kits.
  • a short stretch of DNA surrounding the SNP targets will be sequenced.
  • it is desirable to control the length of sequence reads so that multiple sequencing reactions can be loaded in one lane/capillary without overlapping each other.
  • Figure 6 shows an example of the sequencing reaction.
  • dye-labeled acyclo- ddNTPs were used to assemble the mix.
  • the sequencing reaction was performed using pGEM plasmid and Ml 3 -21 primer.
  • the ratio of dNTPs/ddNTPs and thermal cycling conditions are detailed in the figure legend. The results showed a clean read of 30-40 bases after the primer.
  • the sequences used for the common domains of the two domain were the Ml 3 universal forward primer: cccagtcacgacgttgtaaaacg (for forward outer PCR primers) and Ml 3 universal reverse primer: agcggataacaatttcacacagg (for reverse outer PCR primers).
  • Ml 3 universal forward primer cccagtcacgacgttgtaaaacg
  • Ml 3 universal reverse primer agcggataacaatttcacacagg (for reverse outer PCR primers).
  • the common domain sequence was tcaGCAGCatGTCTCttcca, which contains recognition sites for two restriction enzymes
  • Lane 1 of Figure 7 represents a 4x multiplex PCR using simple primer design. As ca be seen, only two bands are visible (480,510 bp). They could not be resolved by agarose gel electrophoresis. Lane 2 represents the same 4 amplicons, but generated using the two domain design. In this case, the two smaller products (400, 430 bp) are clearly seen. Note the size shifted for the larger products due to extra length (46 bp) in the two domain primers. Lane 3 represents 4x multiplex nPCR with the same amplicons but carried out by the two-step porcedure. In addition to the 4 outer PCR products, 4 inner PCR productscan also be seen.
  • This example is provided to illustrate how a series of sequencible structures are formed from two multiplexed PCRs.
  • a set of five SNPs are selected and nPCR primers are designed using the two domain design.
  • the inner PCR products are arranged to span 150 to 400 bps range, 50 bps apart from one another.
  • the common domain for the inner primers should contain a restriction enzyme recognition site to produce blunt ends after the amplification.
  • Two 5x mulitiplexing PCRs are performed separately: one uses only the outer PCR primers the other uses only the inner PCR primers. After the amplification an appropriate restriction enzyme is used to remove the common tag sequences from the inner end of the inner PCR products.
  • the outer products and the inner products then are combined, purified, denature and reannealed together.
  • a single base extension reaction is performed using the SNaPshot kit from Applied Biosystems.
  • the products then are purified and run on DNA sequencer. The analysis of the extension products will identify the genotypes of the sample.
  • TDI Template-directed dye-terminator incorporation

Abstract

High throughput methods and kits for single nucleotide polymorphism (SNP) genotyping are provided. The methods involve utilizing nested PCR amplification reactions which produce sequencible and ligatible structures. An outer PCR primer set amplifies the SNP, and an inner PCR primer set amplifies a portion of the DNA amplified by the outer primer set, but does not amplify the SNP itself. The inner and outer primers may include non-target common domain sequences, and the inner primer common domain sequences may comprise restriction endonuclease recognition sites. The design of the inner primer set allows precise tailoring of the sequencible and ligatible structures with respect to length and base composition.

Description

MULTIPLE SEQUENCIBLE AND LIGATIBLE STRUCTURES FOR GENOMIC
ANALYSIS
DESCRIPTION
BACKGROUND OF THE INVENTION
Field of the Invention
The invention generally relates to single nucleotide polymorphism (SNP) genotyping. In particular, the invention provides a method for SNP genotyping based on a nested PCR design that creates structures directly suitable for both DNA sequencing and ligation reactions.
Background of the Invention
With the completion of the rough draft of the human genome, over 1.5 million non- redundant SNPs have been identified and mapped by the publicly funded project and the SNP consortium (Sachidanandam et al, 2001).The availability of such a large number of SNPs has prompted great interest in SNP related applications and research, such as large scale linkage, genomic association and pharmarcogenetic studies.
SNPs entered the central arena of genetics due to their abundance (Collins et al, 1997; Sachidanandam et al, 2001), stability (Sachidanandam et al, 2001) and the relative ease (Kwok 2000; Shi 2001; Syvanen 2002) with which they are genotyped. The targets of SNP genotyping are normally small pieces of DNA, ranging from 150-300 base pairs. Based on the SNP consortium report, the average SNP density in the human genome appears to be greater than 1 SNP/KB. This high density provides a tool to analyze genomic structure at very high resolution, and to establish a direct correlation between genetic coding variation and biological function. The relative stability of SNPs (compared to mini- and micro-satellite markers) in evolution makes it simpler to carry out this task. Although SNP genotyping is generally easier than microsatellite genotyping, and despite the rapid and significant advances in SNP genotyping technology in the last few years, major issues remain unsolved. Whereas only a few years ago, the main concern was the need to have a large number of SNPs available, currently the most urgent issues are increasing throughput and decreasing cost. For example, for large scale applications as projected by Kruglyak (1999) and Long (1999), a reasonable cost would be <$0.10/genotype, or else large-scale projects will become prohibitively expensive. To fulfill the goals of understanding the genetics of complex traits and common diseases, cost- effective and higher throughput methodology in SNP genotyping is essential.
Typically, genotyping protocols have three components: target amplification, allelic discrimination and product detection and identification. They are normally executed sequentially, but can be processed in a single step reaction, depending on the means which are used for allele discrimination and signal detection. Such single step procedures are well- suited to automation, but are not necessarily effective in terms of cost and throughput. PCR is the dominant procedure utilized for target amplification. As is widely known, a PCR can readily amplify targets present in lower copy number by a factor of 108 or more. With respect to allele discrimination, all SNP genotyping technologies currently available are based on mechanisms involving one or more of the following: DNA polymerase, hybridization and DNA ligase. DNA polymerase methods include single base extension (SBE) (Armstrong, 2000; Barta 2001; Bray 2001; Cai 2001; Chen 1997; Chem 1999; Chen 1998; Chen 1997; Chen 1997; Fan 2000; Lindblad-Toh 2000;Nikiforov 1994; Pastinen 1996; Pastinen 2000; Ross, 1998; Sauer 2000; Syvanen 1999; Ye 2001), de novo sequencing including pyrosequencing (Nordstrom 2000; Ronaghi 2001), allele-specific
PCR and extension (Germer 1999; Myakishev 2001; Pastinen 2000), and structure-specific cleavage (Fors 2000). Of these different forms, SBE is the most widely used and has been adapted for many different detection platforms. Hybridization is also widely used in several different forms, including dynamic hybridization (Prince 2001), and is the primary method currently used in all microarray detection formats. DNA ligase methods are based on the ability of DNA ligase to join the ends of two oligonucleotides annealed next to each other on a template (Tong 2000; Tongl999). Two oligonucleotides can be designed to anneal to both sides of a SNP site, and by detecting the formation of ligation product, the genotype of a target can be inferred (Chen 1998; Delahunty 1996; Gerry 1999; Iannone 2000). Once a target DNA sequence has been amplified and the allelic variants discriminated, the next step in a generic genotyping protocol is to detect and identify the allele specific products. Detection mechanisms vary greatly, from simple fluorescence intensity (Armstrong 2000; Cai 2000;Chen 1998; Chen 1997; Delahunty 1996; Dubertret 2001; Fan 2000; Fergusoon 2000; Fors 2000; Germer 1999; Germer 2000; Gerry 1999; lannone 2000; Lindblad-Toh 2000; Lindroos 2001; Marras 1999; Medintz 2001; Myakishev 2001; Nikiforov 1994; Pastinen 1997; Pastinen 2000; Prince 2001; Syvanen 1999; Ye 2001) to very precise mass (Bray 2001; Ross 1998; Sauer 2000) or electric charge (Gilles 1999; Woolley 2000) measurement. The detection mechanisms roughly fall into two categories: homogeneous and solid phase mediated detection. All homogeneous detection platforms depend on measuring fluorescence intensities and their change during and/or after reactions. One common feature among homogeneous approaches is that they do not require any separation/purification prior to signal acquisition, making them amenable to automation. Solid support techniques include flow cytometry genotyping (Armstrong 2000; Cai 2000; Ye 2001), zip-code microarrays (Fan 2000; Gerry 1999), and mass spectrometry genotyping (Bray 2001; Ross 1998; Sauer 2000). Using a solid support in the detection step may potentially increase throughput and reduce cost, but unfortunately also entails the risk of complicating protocols and compromising data quality. For example, when reaction mixtures are applied to a solid support, unintended binding of fluorescence dye to the solid surface can occur, necessitating extensive washing to minimize spurious signals.
With respect to cost, prices for genotyping technologies currently available on the market vary considerably, from $0.50-2.00/genotype. For example, the template-directed dye-terminator incorporation assay with fluorescence detection (FP-TDI) (Chen 1999) costs roughly $0.50/genotype for reagents by list price. For other methods, due to their requirement for special reagents and/or clean-up procedures, the cost is higher, e.g. MALDI-TOF mass spectrometry is about $0.75-1.00, whereas pyrosequencing approaches $2.00/genotype. No currently available technology approaches the low cost which is necessary in order to prevent large-scale projects from becoming prohibitively expensive, i.e. <$0.10/genotype.
There are currently many genotyping applications in use or under development that require a relatively large number of both SNPs and samples (e.g., both in the thousands or more), demanding both cost effective and high throughput technologies. Examples include gene mapping studies by linkage or linkage disequilibrium (Kruglyak 1999; Long 1999) for complex traits and pharmacogenetics (Riley 2000). Clearly, these applications are critical to improving our understanding of the genetics of complex traits, common diseases and drug response, and to help attain the goal of individualized medicine. However, none of the current approaches are suitable for such applications in terms of cost effectiveness coupled with high throughput potential, and SNP genotyping demands both.
SUMMARY OF THE INVENTION
The present invention provides a methodology for high-throughput SNP genotyping that is highly cost effective. This novel approach makes use of the high throughput capacity of DNA sequencers for SNP genotyping and is based on a nested PCR design that creates a series of ordered "structures" in parallel and exploits them for SNP genotyping assays. The invention thus provides novel genotyping technologies that significantly increase throughput, reduce cost and are accessible for most researchers, leading to significant improvements in genotyping technology. While typical SNP genotyping approaches currently available score <10 SNPs simultaneously, the methods of the present invention increase the number to about 50-100 with obvious advantages for throughput and cost. The present invention provides a method of producing hybrid DNA with a single strand overhang that includes a target sequence. The steps of the method include: obtaining a first primer which hybridizes to a 5' strand of a strand of deoxyribonucleic acid (DNA), a second primer which hybridizes to a 3' strand of the strand of DNA, and a third primer which hydridizes to said 3' strand of DNA; producing by nested polymerase chain reaction (PCR) using the first primer, the second primer, and the third primer, an outer amplicon which includes a target sequence and an inner amplicon which excludes the target sequence; forming at least one of the following: a ligatable structure which includes a 3'-5' sequence which excludes the target sequence hybridized to a 5'-3' sequence which includes the target sequence, and a sequencible structure which includes a 5 '-3' sequence which excludes the target sequence hybridized to a 3'-5' sequence which includes the target sequence; sequencing the sequencible structure(s) and ligating the ligatible structure(s) with a labeled oligonucleotide; and analyzing the sequencing products and ligation products with a DNA sequencer to determine the genotype of said individual. The method may form both the ligatible structure and the sequencible structure. The target sequence(s) may include a single nucleotide polymorphism.
The invention also provides a method of genotyping the deoxyribonucleic acid (DNA) of an individual by analyzing at least on target sequence in the DNA. The steps of the method include: obtaining a first primer which hybridizes to a 5' strand of a strand of said DNA, a second primer which hybridizes to a 3' strand of the strand of DNA, and a third primer which hydridizes to the 3' strand of DNA; producing by nested polymerase chain reaction (PCR) using the first primer, the second primer, and the third primer, an outer amplicon which includes said target sequence and an inner amplicon which excludes the target sequence; and forming at least one of the following: a ligatable structure which includes a 3'-5' sequence which excludes the target sequence hybridized to a 5'-3' sequence which includes the target sequence, and a sequencible structure which includes a 5'-3' sequence which excludes the target sequence hybridized to a 3'-5' sequence which includes the target sequence; sequencing the sequencible structure and ligating the ligatible structure with a labeled oligonucleotide; and analyzing the sequencing and ligation products so produced with a DNA sequencer to determine the genotype of the individual. The forming step of the method may form both the ligatible structure and the sequencible structure. The target sequence(s) may include a single nucleotide polymorphism. The sequencible structure may be sequenced by a technique such as dideoxy sequencing, pyrosequencing, and single base extension. In a preferred embodiment, of the method, i) a plurality of target sequences is analyzed; ii) the step of forming forms an ordered series of sequencible structures; iii) the step of sequencing produces an ordered series of sequencing products of varying, non- overlapping length; and iv) the step of analyzing is carried out by electrophoresing the ordered series of sequencing products in a single channel of said DNA sequencer. In some embodiments, the step of sequencing is carried out by single base extension (SBE).In other embodiments, the step of sequencing is carried out by a dideoxy sequencing reaction utilizing a ratio of dNTPs to ddNTPs that is lower than that which is typically used in order to produce a short sequence reading.
In a preferred embodiment of the present invention, the labeled oligonucleotide is fluorescently labeled.
In one embodiment of the method, i) a plurality of target sequences is analyzed; ii) the labeled oligonucleotides are degenerate; iii) the ligation products are of varying, non- overlapping lengths; and iv) the step of analyzing is carried out by electrophoresing a plurality of ligation products in a single channel of said DNA sequencer.
The present invention also provides a method for analyzing at least one target site in a DNA molecule. The method includes the steps of:l) amplifying the target site(s) by nested PCR; (The nested PCR is carried out using inner and outer PCR primer pairs, wherein the outer PCR primer pair forms a first PCR product which contains a target site, and the inner PCR primer pair forms a second PCR product which contains a portion of the first PCR product but does not contain the target site); 2) denaturing the first and said second PCR products to form ssDNA sequences, 3) reannealing the ss DNA sequences to form a sequencible hybrid DNA molecule and a ligatible hybrid DNA molecule, 4) performing sequencing reactions with said sequencible hybrid DNA molecule and ligation reactions with said ligatible hybrid DNA molecule, and 5) determining the characteristics of the target sequence by analyzing results obtained in the performing step. In a preferred embodiment of the method, the target site(s) may be SNP polymorphism sites. Further, the inner and outer primer pairs may comprise a sequence tag, which in turn may comprises a restriction enzyme recognition site. In some embodiments of the method, the step of amplifying may be carried out using a low concentration of primers, and may further comprising a second step of amplification using secondary primers for amplification of the sequence tags. According to the method, one or several target sites may be analyzed. The step of amplifying may be carried out in a single multiplex PCR reaction, or in multiple independent PCR reactions, and the results may be analyzed by a DNA sequencer.
The invention also provides inner and outer PCR primer pairs for the amplification of a target sequence in a DNA molecule, wherein the outer PCR primer pair forms a first PCR product which contains the target sequence, and the inner PCR primer pair forms a second PCR product which contains a portion of the first PCR product but does not contain said target sequence. The target sequence may be an SNP polymorphism site. The primer pairs may comprise a sequence tag.
The present invention also provides a kit for amplification of at least one target sequence in a DNA molecule. The kit includes inner and outer PCR primer pairs for the amplification of the target sequence. The outer primer pair amplifies a portion of the DNA molecule which includes the target sequence, and the inner primer pair amplifies part of the same portion of the DNA molecule that is amplified by the outer primer pair, but excludes the target sequence. The inner and outer PCR primer pairs may comprise sequence tags.The kit may further comprise secondary primers for the amplification of the sequence tags. The present invention also provides a dideoxy DNA sequencing kit for producing short chain termination fragments. The kit includes dNTPs and ddNTPs which are present in a low dNTP:ddNTP ratio.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. A schematic drawing illustrates a nested PCR design that would create both a sequencible and a ligatible structure. The reaction uses two primer sets (inner and outer). PI, forward outer and forward inner primer; P2, reverse inner primer; P3, reverse outer primer. When this design is multiplexed, multiple sequencible and a ligatible structures are formed. These structures can be used for genotyping reactions.
Figure 2A and B. A, a multiplex PCR scheme that amplifies three target sites. Two primer sets (inner and outer) are used for the amplification of each target site. The target sites are represented by "x". All primers contain two domains, a common domain and a target specific domain. The target specific domains, indicated by arrows, have sequences unique to the targets, whereas the common domains are not target specific. D = common domain of forward inner and forward outer primers; I = common domain of inner reverse primers; = common domain of reverse outer primers. B, close-up view of common domain of inner primer shows restriction sites incorporated into the sequence of the domain.
Figure 3 A and B. A. Depiction of nested PCR primer design. The sequence (SEQ ID NO.
1) represents 393 nucleotides from human chromosome 6. Nucleotides corresponding to primer pairs are shaded with gray, and arrows indicate primer orientation. Arrow indicates site of polymorphism. The sequence which was generated by ABI 377 sequencer is shown in italics, and is also depicted in Figure 3B (SEQ ID NO. 2). The sample is a A/A homozygote.
Figure 4A and B. A. Depiction of nested PCR primer design. The sequence (SEQ ID NO.
3) represents 494 nucleotides from human chromosome 6. Nucleotides corresponding to primer pairs are shaded with gray, and arrows indicate primer orientation. Arrow indicates site of polymorphism. The sequence which was generated by ABI 377 sequencer is shown in italics, and is also depicted in Figure 4B (SEQ ID NO. 4). Two samples were shown in Figure 4B. The upper panel was a heterozygote (C/T), at base position 24, as pointed by the arrow, both bases © and T) were identified. The lower panel was a homozygote (T/T), at the indicated position only the T base was identified. The example demonstrated that a single nucleotide polymorphism (SNP) could be identified by sequencing from the sequencible structure formed from the nPCR design. Figure 5. SBE genotyping using sequencible structures from nPCR products amplified by Pfu DNA polymerases. Nested PCR primers were designed for an SNP marker from human chromosome 6. The inner product size is 189 bp, its 3' end is positioned immediately upstream to the polymorphic site when it forms sequencible structures. PCRs were performed with DNA samples of known genotypes. After PCRs the outer and inner products were purified and denatured together to form sequencible structures. SBE reactions were performed and products analyzed in ABI 377 Sequencer using Genescan. Three samples were presented. The upper panel is a homozygous A/A where an SBE product of 190 bp is found (arrow). Products of the same size are found in the heterozygous (middle panel) and the other homozygous (lower panel). The peaks after the dye front are ROX500 size makers (35, 50, 75, 100, 139, 150, 160, 200, 250 bp respectively). Figure 6. An example illustrates a short sequence read with a specially assembled sequencing mixture that has a different ddNTPs/dNTPs ratio. The components used for the example were the following: 1.75 μM of -21 M13 primer, 300 ng of pGEM, 60 μM of each dNTPs, 2.5 μM of R6G-acyclo-ATP, 12 μM of ROX-acyclo-CTP, 10 μM of BODIPY- Fluorescein-acyclo-GTP, 25 μM of TAMRA-acyclo-UTP, 1 unit of AcycloPol DNA polymerase and lx AcycloPol reaction buffer. The thermal cycling conditions were 96 °C for 3 min., followed by 25 cycles of 96 °C for 1 min., 50 °C for 15 sec. and 60 °C for 4 min. Figure 7. Primer designs affected multiplex PCR and nPCR. Lane 1 was a 4x multiplex PCR with simple PCR design, Lane 2 was the same 4 amplicons but with the two domain design, and Lane 3 was the 4x multiplex nPCR with the same amplicons performed in two sequential reactions. In the first reaction, equal amount of primary primers at 10 nM were used. The cycling condition was 95 °C for 10 min, followed by 10 cycles of 95 °C for 45 sec, 65 °C for 5 sec, ramping to 55 °C at 0.1 °C/sec and 55 °C for 90 sec. For the second reaction the primers used were different among the three lanes. Lane 1, since it did not have secondary primers, the same primers were used as in first reaction but the concentration increased to 100 nM. Lane 2 used two secondary primers, Ml 3 forward and reverse, each 400 nM. Lane 3 used three primers, Ml 3 forward (600 nM), Ml 3 reverse (400 nM) and the common tag for inner PCR primers (400 nM). The cycling conditions for the second reaction was following: 95 °C for 10 min, followed by 30 cycles of 95 °C for 45 se , 55 °C for 90 sec.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION
The present invention provides methods of high-throughput SNP genotyping that are highly cost-effective. The methods utilize the high-throughput capability of ubiquitous and readily accessible DNA sequencers in order to carry out the SNP analysis. This is possible due to the experimental design of the methods, which are based on nested PCR reactions. In a preferred embodiment, the target sites which are analyzed are SNP polymorphism sites.
However, those of skill in the art will recognize that other target sites may also be analyzed by the methods of the present invention. For example, short insertions and deletions, and closely spaced multiple SNPs can be identified by the multiple target sequencing approaches disclosed herein. As is well-known to those of skill in the art, nested PCR is a PCR amplification method that "nests" one PCR reaction within another. Two sets of primers are used: "outer" primers amplify a portion of a DNA strand, and "inner" primers amplify a smaller portion of the same DNA that is located within the larger, outer portion. Thus, two PCR products (amplicons) are produced. One amplicon is smaller than the other and contains a "subset" of the bases contained in the larger, outer amplicon
In the practice of the present invention, a new design for nested PCR is used. Primers are designed so that the outer amplicon includes a target site (e.g. an SNP polymorphism site) and the inner amplicon excludes the target site. The purpose of the inner PCR in the nested reaction is to synthesize a DNA fragment whose size and position relative to the outer PCR can be precisely controlled. This design concept is illustrated in Figure 1. As can be seen, in Figure 1, the inner primer set is composed of primers PI and P2, and the outer primer set is composed of primers PI and P3. (In this example, Primer PI is utilized in both primer sets.) The P1-P3 outer primer set flanks the indicated target site whereas the P1-P2 inner primer pair does not. PCR amplification of the DNA with these primers will produce two amplicons. The larger of the two is the outer amplicon formed by amplification with the P1-P3 pair; this amplicon includes the target site. The smaller of the two amplicons, the inner amplicon, contains base pairs which lie within the bounds of the larger outer amplicon (i.e. is "nested" within the larger amplicon) , but does not contain the target site. The ultimate product of the PCR reaction is double strand DNA of two lengths, only one of which (the longer) contains the target site, and the shorter of which contains a subset of the bases contained in the longer strand.
In a preferred embodiment of the invention, the same primer functions as both the outer and inner forward primer. However, those of skill in the art will recognize that this need not be the case. With reference to Figure 1, a distinct forward inner primer ("P4", shown in parentheses) might be designed to anneal between PI and P2 and in the orientation of primer PI . Because the shorter amplicon contains bases which are identical to a portion of the longer amplicon, when the ds strands are denatured and allowed to reanneal, some (approximately 50%) of the shorter single strand DNA of the inner amplicon will hybridize with matching portions of the single strand DNA of the outer amplicon. This cross hybridization between the two amplicons creates two different inner-outer "hybrid" structures as depicted in Figure 1. In one of the two structures, the "ligatible structure" of Figure 1, a 3' overhang will be present, the bases of which originated from the outer amplicon and contain the target site. This structure can be used, for example, for ligation based applications. By "ligation based applications" we mean the smaller amplicon is one of the two or more pieces of DNA that are joined together by a DNA/RNA ligase. In the other structure, the "sequencible structure" of Figure 1, a 5' overhang will be present, the bases of which originated from the outer amplicon and also contain the target site. This second type of structure will be directly amenable to sequencing applications. By "sequencing applications" we mean that the smaller amplicon acts as a sequencing primer to sequence the DNA downstream from it. The sequencing can be only one base in length (i.e. SBE) or in the tens or in the hundreds of bases. Thus, in a single nested PCR reaction followed by denaturation and annealing, it is possible to generate both sequencible and ligatible structures. Of course, some (approximately 50%) of the single strand DNA will renature to form the original ds PCR products ("structures same as products" in Figure 1). Years of improvement in primer design and thermocycling conditions have increased the success rate for single target PCR reactions to greater than 90%. However, multiplex reactions such as those in a nPCR reaction, have a much lower success rate and extensive optimization is typically required, usually because it is very difficult to obtain amplified products in equal amounts. The usual solution is to increase the primer concentration for the weakly amplified target(s). This suggests that it is annealing efficiency that is responsible for the unequal amplification. In US Patent 5,882,856 to Shuber, the complete contents of which is herein incorporated by reference, an alternative solution is proposed in which all primers utilized have two domains, one which is target specific as in regular PCR designs, and one which is a "common domain". For a set of PCR primers to be multiplexed, two common domains are utilized. A first common domain is a sequence shared by all forward primers and is attached at the 5' end of the target specific domain. A second common domain sequence is shared by all reverse primers and is attached at the 5' end of the target specific domain. The common domain facilitates annealing of different primer sets because the common domain has a higher annealing temperature than the target specific domain. In the practice of the present invention, common sequence domains or "sequence tags" as taught by Shuber may be utilized for both inner and/or outer PCR primers. The common sequence tag for the outer PCR primers would help in multiplexing PCR so that amplification would result in the production of equal amounts of product. The common sequence tag for the inner primers also serves to even the levels of PCR products, and in addition may provide restriction sites that can be used to generate precise fragment ends for genotyping reactions such as sequencing and/or ligation reactions. The combination of incorporating special restriction enzyme recognition sequences in such a sequence tag, and the deliberate positioning of the inner PCR primers make it possible to precisely tailor the resulting PCR products for any of a variety of purposes, including but not limited to primer extension, sequencing, ligation, pyrosequencing, structure specific cleavage, and other genotyping reactions. Those of skill in the art will recognize that placement of the P2 primer can be anywhere between the target site and the other primer of the inner primer pair, so long as a useful PCR product is produced by PCR amplification of the inner primer pair, and the target site itself is not amplified. The positioning of the P2 primer relative to the target SNP may vary depending on the mechanism of the genotyping reactions. For example, for SBE reactions, the end of the primer should be immediately 5' to the SNP site. For Multi-Target Sequencing (MulTarSeq) reactions, there may be a gap between the end and the target SNP site. In a preferred embodiment, for MulTarSeq reactions the gap may be from about 1 to 50 bases, or more preferably from about 5 to about 20 bases, and most preferably from about 10 to about 15 bases. Further, as described above, the desired length of the final product from the amplification of PCR primers containing common sequence tags may also be determined by the presence of a restriction enzyme cleavage site within the tag.
In yet another embodiment of the present invention, the amplification reactions may be carried out in a step-wise fashion using primary and secondary primers. In this embodiment, a single PCR is divided into two sequential reactions, the first of which uses the primary primer set and the second of which uses the secondary primer set. The primary primers may be designed to have two domains (target specific and common) as described above. The secondary primer set contains only the common tails from the primary primers. For the first reaction, the primary primers are used in only limited but equal amounts, e.g. about 1-5% of the amount for a regular PCR i.e. about 0.1 to about lOOnM. The rationale is that by limiting the amount of primers for each set multiplexed in the reaction, the system is forced to produce limited but equal amounts of products for all amplicons. When the more robust primers are used up (because of the limited amount available) the system will work with the less efficient primers. The purpose of the primary PCR is to amplify enough templates from the genomic DNA to carry out the secondary PCR. Since all primary primers have limited but equal amounts, this forces the primary PCR to produce limited but near equal amounts of templates for the secondary PCR. For the secondary PCR, the secondary primers, consisting of only one set for all primary amplicons, is used. In essence this secondary reaction is a single PCR that amplifies multiple templates. The net result of this two-step PCR process is to compensate for differences in efficiency across PCR reactions. The purpose of the inner PCR in the nested reaction is to synthesize a DNA fragment whose size and position relative to the outer PCR can be precisely controlled. By altering the position of the P2 primer relative to PI, and by optionally including sequence tags with restriction sites, it is possible to design longer or shorter PCR fragments. The synthesized fragments can then be used in any of a variety of genotyping reactions, including but not limited to primer extension, sequencing, ligation, pyrosequencing, structure specific cleavage, and the like.
For example, the sequencible structure fragments may be used as extension primers in SBE and MulTarSeq reactions. The direct production of sequencible structures by the methods of the present invention thus permits investigators to take advantage of the ready availability of DNA sequencers for the purposes of genotyping. Relatively long primers can be synthesized in this manner in a feasible and much more cost effective way than, as is typically done, by chemical synthesis. For example, the length of such a fragment can range from about 35 to about 1000 bps, and is preferably in the range of about 50 to about 650 bps. To use a standard sequencing reaction to determine the sequences surrounding a polymorphic site, it is simply necessary to add an appropriate sequencing mixture without using any sequencing primer, because the sequencible structure provides the free 3' end for the sequence reaction.
Those of skill in the art will recognize that several methods of sequencing are well established, and that new sequencing methodologies are continually being developed. In the practice of the present invention, any suitable method of sequencing may be utilized. Examples of such methods include but are not limited to Sanger (dideoxy)-based sequencing methods and pyrosequencing.
The procedure illustrated in Figure 1 amplifies a single target and relies on multiplex PCR amplification since more than one pair of primers is used in a single reaction. However, those of skill in the art will recognize that in many cases it will be desirable to amplify more than one target site at a time. In this case, the design of the inner primer pairs for each target site may be such that an ordered series of PCR products of varying lengths is produced, i.e. the sequencible structure formed for each target site differs in length from the sequencible structures formed for each of the other target sites. (See
Figure 2A). For example, an ordered series of sequencible structures from about 50 to about 500 bps in length can be designed, thus adding an additional distinguishing feature to each of the amplified target sites. Because of this feature, multiple sets of PCR products can be sequenced in a single reaction providing that the length of sequencing is limited so that their chain termination fragments do not overlap in a sequencing gel. This would allow the sequencing of multiple targets in a single reaction and analysis in a single channel (e.g. a lane or capillary).
Those of skill in the art will recognize that several ways exist to control the length of reading for sequencing reactions. For example, the length of reading can be adjusted by changing the ratio of ddNTP/dNTP in the reaction mixture. For standard Sanger sequencing reactions, the ratio is typically about 1 : 100, a ratio intended to promote relatively long reads (e.g. about 600-800 bps). Those of skill in the art will recognize that, by systematically altering and testing the ratio, it is possible to find the optimal reading length for a given application. For most SNP genotyping purposes, a read of from about 1 to about 50, and preferably from about 1 to about 25 bases would be sufficient, requiring a low ddNTP/dNTP ratio of preferably in the range of about 1 :0 to about 1:10, and more preferably about 1 :0 to about 1:5. For other applications, the optimal length can be attained by adjusting the ratio, i.e. the ratio may be optimized by methods which are well known to those of skill in the art in order to achieve the desired sequence read length. Precise control of the read allows very high level multiplexes to be carried out (e.g. 100 to 200x). In order to carry out the practice of the present invention, primer design involving placement of the primer and the optional addition of a sequence tag must be carried out. Further, those of skill in the art will recognize that other factors influence primer design and must be taken into account as well. For example, the exact sequence of bases will influence the strength of the hybridization of the primer with its cognate DNA (the sequences of based to which it binds during PCR) and thus must be taken into account when planning PCR amplification protocols; the possibility of primer-dimer formation is taken into account, as is the potential for the formation of secondary structure, etc. Those of skill in the art are well acquainted with such issues and numerous resources exist to aid the skilled practitioner in these various aspects of primer design. As discussed above, the common domains of the inner primers may be designed to include restriction enzyme recognition sites. The restriction enzymes preferred are those that cleave DNA strands downstream from their recognition sites and generate blunt ends products. For sequencing applications restriction enzymes that cleave DNA downstream and generate 3' overhangs can also be used. For ligation applications restriction enzymes that cleave DNA downstream and generate 5' overhangs can also be used. Examples of such sites include but are not limited to these enzymes: Mly I, Fst F51, Bpm I, Eco571, Bsg I, Eci I, Bst71 1, Alw26 1, Ksp62 1, BceA I, etc. The other nucleotides in the sequence of a common domain inner primer are selected to balance the melting temperature with that of the common domain of the outer primers. With respect to the design of common domain sequences for outer primers (i.e. those which do not contain restriction sites), the sequences are selected so that so it will match the melting temperature of the common domain of the inner primer.
In general, the generation of the sequencible and ligatible structures of the present invention will be carried out as follows: a PCR amplification reaction is carried out, followed by a restriction with a suitable restriction enzyme if a restriction site was incorporated into a common sequence tag of the inner primers. This is followed by treatment to "clean up" the reaction e.g. with shrimp alkaline phosphatase (SAP) and exonuclease I (Exo I) to degrade excess PCR primers and dNTP left over from the PCR reaction, and to remove the overhanging ends of restriction digestion. (Alternatively, filtration via sephadex gel may also be employed.) After S AP/Exo I digestion, a high temperature denature step is performed. This denature step serves two purposes: one is to inactivate both SAP, Exo I and the restriction enzyme; the other is to completely denature double stranded DNA. During the cooling process that follows, the four single stranded DNA fragments from the two PCR products will form four kinds of structure. Two of them are the exactly same as the PCR products and are both blunt ended. Two new structures formed between the complementary strands of the large and small PCR products, one of them with a 5' end single stranded, the other one with a 3' end single stranded. The one with a 5' end single stranded provides a free 3 'end for sequencing reaction/primer extension and for ligation, and is referred to as a "sequencible structure". The one with single stranded 3' end provides a free 5' end for ligation, and is referred to as a "ligatible structure". These four structures will have equal concentrations if the quantity of the two PCR products is equal. In this case, the sequencible and ligatible structures will represent about 50% of the reannealed products. This amount is sufficient for both sequencing/primer extension and ligation reactions to make new products.
In some embodiments of the present invention, a single target site is analyzed by the methods of the present invention, and the PCR step is carried out by multiplex PCR, i.e. amplification with both the inner and outer primers is carried out in the same reaction.
However, those of skill in the art will recognize that two separate PCR reactions may also be carried out, i.e. the inner and outer PCR reactions are carried out separately. In this case, the PCR products from the two reactions may be combined later at some point prior to the renaturation step so that the single strands can reanneal. Similarly, in other embodiments of the present invention, it may be desirable to PCR amplify more than one target site at a time. In some cases, this may be carried out by a multiplex PCR reaction in which inner and outer primers for all target sites of interest are amplified simultaneously in a single reaction. Alternatively, one or more sites may be amplified together, or each site may be amplified alone, either in a single reaction with both inner and outer primers, or in two reactions, one for the inner and one for the outer primers as described above. Any combination of PCR amplification reactions may be utilized in the practice of the present invention, so long as the procedure results in the production of suitable sequencible and/or ligatible structures.
In a preferred embodiment, the present invention provides methods which ultimately utilize DNA sequencers or the like to detect the products formed from sequencible and/or ligatible structures created by the present methods. Those of skill in the art will recognize that many suitable techniques exist by which the sequencible products can be produced for analysis by a DNA sequencer. Examples include but are not limited to Sanger-type sequencing reactions, single base extension (SBE), and pyrosequencing. Ligatible structures may be analyzed directly on a DNA sequencer after a labeled oligonucleotide (e.g. fluorescently labeled) is joined to the 5' phosphate of the ligatible structure via a ligation reaction.
Those of skill in the art are well acquainted with Sanger-type sequencing reactions, which are based on the interruption of enzymatic extension of the DNA chain at the 3' hydroxyl via incorporation of 2'-3 '-dideoxy analogs. Four sets (one for each dideoxy analog) of such chain-terminated fragments of differing lengths are generated and "read" (detected) by a DNA sequencer to yield a sequence. Typically, the fragments are labeled with radioactivity or fluorescent tags for detection.
Single base extension is essentially a sequencing reaction, the difference being that SBE uses only dye-terminators, resulting in the extension of the primer by only a single base. As described above, in the practice of the present invention, the length and position of the extension primer relative to the polymorphic site may be controlled so that it is possible to create a primer which anneals immediately upstream of a polymorphic site. Then, in a regular SBE reaction, the polymorphic base can be determined by identifying which base(s) is incorporated into the primer. If several target sites are to be analyzed, a set of primers can be designed which, upon amplification of the targeted DNA, produce an ordered set of such sequencible structures of varying, non-overlapping lengths. When such structures are extended by dye-labeled ddNTPs, an ordered series of SBE products of varying, non- overlapping lengths is produced. In the proposed nested PCR design, because extension primers from about 50 to over 500 bases can be obtained, it is possible to separate these SBE products in a sequencing gel/capillary. A regular sequencing gel can sequence about 500-800 bases. Therefore, over 100 SNPs can be analyzed in a single channel by loading their corresponding SBE products in one lane/capillary when the extension primers are designed to be positioned, for example, every 4-5 bases apart for a full range of 500-600 bases. In order to successfully carry out SBE reactions, the ends of the primers must be precise, i.e. it is necessary to control precisely where the inner amplicon ends. The use of Taq DNA polymerase may in some cases be disadvantageous due to its known extendase activity which interferes with such precision. Those of skill in the art will recognize that a variety of means are available to overcome such a problem. For example, the use of high fidelity polymerases may be employed. Pfu DNA polymerase is a well characterized DNA polymerase that has been shown to have high fidelity of replication (Cline 1996). It is known that Pfu DNA polymerase does not add extra A's at the 3' end (Cline 1996; Hu 1993). Based on a study by Cline et al (Cline 1996) the use of Pfu DNA polymerase gives precise ends of inner PCR products. A second alternative is to use ribonucleotides and/or abasic analogs in the inner primer to control DNA polymerases' end point. Some DNA polymerases do not have reverse transcriptase activity, Pfu and Vent polymerases are examples (Perler 1996). These enzymes can not incorporate any nucleotide when they encounter a ribonucleotide base in a template. Coljee et al recently reported a strategy to create precise overhang at the ends of PCR products by using ribonucleotides (Coljee 2000). The strategy inspired us to use same mechanism to control the ends of inner PCR products. Thus, inner primers may be designed to overlap the target SNP site, at the SNP site, instead of using regular deoxyribonucleotide, a ribonucleotide is used. DNA polymerases can use a chimeric oligonucleotide as primer efficiently (Gal 2000; Stump 1999), so the use of chimeric primers would not compromise PCR efficiency. When the complementary strands are synthesized, the DNA polymerases will stop one base before the ribonucleotide base in the chimeric inner primers, creating very accurate and precise ends for SBE. It is also possible to create chimeric primers containing several ribonucleotide bases to create several base overhang for the purpose of ligation (Coljee 2000). Similarly, a nucleotide analog that does not contain the base, the abasic analog, has similar effects on DNA polymerase (Gal 2000; Gal 1999) and may be used.
Yet another alternative is to use restriction enzymes to produce precise 3' ends for sequencible structures. There are some restriction enzymes that cleave DNA strands downstream from their recognition sites, e.g. KSP632 1, Alw26 I, and Bst71 1. As discussed above, to take advantage of these features, a common domain (sequence tag) may be added to the 5 ' end of the inner PCR primers. The common domains contain restriction enzyme sites which can be positioned so that the 3' extending ends are located just before the polymorphic sites after the tail is cleaved off. The use of a common domain for inner primers could also help to even the amounts among different amplicons when multiplexed. Pyrosequencing is a unique technique that incorporates a sequencing reaction and real time detection together. Since, as in a regular sequencing reaction, pyrosequencing uses
DNA polymerase, the free 3' termini in the sequencible structures can function as extension primers. Since pyrosequencing is a real time system, it is not amenable to the analysis of multiplex reactions. There would thus be no need to use a common tail for the inner PCR primers. The primers for a reaction whose products are destined for analysis by pyrosequencing are designed to accommodate the needs of pyrosequencing, preferably from about 5 to about 8 bases upstream of the target polymorphic site. The ligatible structures produced by the methods of the present invention have a free 5' phosphate. If a common tag is included in the design, when the common tag is removed from the inner PCR products, restriction enzyme digestion leaves the 5' phosphate on the ligatible structure. To make such a ligation site at a polymorphic site, the cleavage site of restriction enzymes used in the inner PCR primer must be immediately down stream of the polymorphic site on the complementary strand. Those of skill in the art will recognize that, because all of these restriction enzymes produce a 5' over hanging strand, a suitable design of restriction site for ligation assay would not be suitable for SBE reaction, but could be used for MulTarSeq reaction. Further, one advantage of the use of ligation to score a polymorphism is that it can be combined directly with the PCR reaction, resulting in a closed tube assay.
To be detected by a DNA sequencer, DNA fragments have to be labeled with fluorescence dyes. In the present nested PCR design, the PCR products are not labeled with any fluorescence dye. Thus, the ligatible structures can be detected only if they are ligated to a labeled oligonucleotide, e.g. one that bears a fluorescent label. To be ligated onto a ligatible structure created by restriction enzyme digestion and subsequently detected by a DNA sequencer, an oligonucleotide would have a 3' OH group and 5' fluorescence labeling. Current DNA sequencers typically analyze fluorescence with a spectrum between 510-610 nm. Those of skill in the art will recognize that there are many fluorescence dyes available in this range. For example, the BODIPY series of fluorescent dyes have been shown to minimize emission overlaps between dyes (Metzker 1996). Examples of other dyes which may be utilized to carry out this aspect of the invention include but are not limited to FAM, fluorescein, Rl 10, R6G, TAMRA, ROX, Texas red, etc.
If only a single locus is of interest is to be analyzed, locus-specific fluorescence- labeled oligos may be utilized. However, in order to carry out high level multiplex reactions, sets of degenerate, fluorescence-labeled oligos are desirable. For example, in order to make ligatible structures suitable for high throughput genotyping assays, a common set of four fluorescence dye labeled degenerate oligonucleotides may be utilized. The degeneration of the oligonucleotides is to make them reusable for all potential assays. If an oligonucleotide with a specific sequence is used, it would only work for one particular target. Several important issues must be taken into consideration regarding the design of the degenerate oligonucleotides. One is the length of the oligonucleotide, which effects both ligation efficiency and the concentration of a specific sequence in the degenerate oligo population). For example, for a 6-7 mer oligo containing 5 -6 degenerate bases, any given sequence would have a concentration of l/43-l/44 (i.e. 1/1024-1/4096). If the total concentration for a 7-mer degenerated oligo used in ligation is 1 μM, the effective concentration for any giving sequence would be greater than 0.2 nM, a concentration at least 100 fold above the detection limit of sequencing gel/capillary. Those of skill in the art will recognize that the optimal length of the degenerated oligo and its concentration may vary from experiment to experiment, depending on the level of degeneracy and multiplex used in the reaction.However, the oligo will generally be in the range of about 5- about 20 bps in length with from about 4 to about 19 degenerate bases, and more preferably in the range of about 6 to about 8 bps in length with about 4 to about 6 degenerate bases. Another consideration is the melting temperature for the degenerated oligonucleotide. As is well known to those of skill in the art, the Tm will vary depending on factors such as the GC content, the length of the oligo, and the like. For example, increasing the GC content and/or the length of an oligo increases its Tm. Increasing the length of oligonucleotide will increase Tm, but would decrease the effective concentration for a specific sequence. In addition, other factors such as the ionic strength of the ligation buffer also affect Tm significantly. Other considerations involved in oligo design which are well- known to those of skill in the art include the number and position of bases which are degenerated. The number of degenerated bases will have a significant impact on the effective concentration and Tm. For example, if 5 degenerated bases are used within a 7 mer, 16 oligos must be synthesized, but if 6 degenerated bases are used, only 4 oligos are necessary. While one specified position must match the polymorphic site if multiple specified positions are used, the position does not necessarily have to be the last one on the 3' end. Further, the position of the ligation site relative to SNP site (the 5' end or the 3' end) may also be altered to optimize a given experiment. Previous studies (Tong 2000; Tong 1999) have suggested that DNA ligase exhibits better allelic discrimination when the ligation site is on the 3 ' end.) Those of skill in the art will recognize that many tools exist and are well-known to the skilled practitioner for optimizing such parameters, thereby facilitating the design of suitable oligos. (See, for example, Delahuntyl996, Tong 2000; Tong 1999). Examples include but are not limited to various computer soft ware packages such as DNA Star, Oligo, Primer Express, etc.
Other factors which may be considered include the type and concentration of ligase to be employed. For example, a 6-7 mer oligo with a moderate GC content should exhibit a melting temperature between 30-40 °C, a Tm sufficient to perform a cyclic ligation assay. The use of thermal stable DNA ligase would provide an opportunity for multiple cycling of a ligation assay at this temperature, which would compensate for lowered efficiency of the reaction. Those of skill in the art will recognize that a plethora of protocol references, kits, etc. are readily available to facilitate carrying out such manipulations of the DNA. The precise nature of the protocols which are used is not a central feature of the present invention, and any of many suitable means for carrying out the various steps of PCR amplification and detection and analysis of the amplicons may be utilized in the practice of the present invention.
Those of skill in the art will recognize that a variety of additional well-known techniques may be reliably utilized in the practice of the present invention, examples of which include but are not limited to: mass spectroscopy, ELISA techniques, fluorescence intensity/energy transfer/polarization, various micro assays (e.g. DNA/RNA arrays), microfluidic devices, and magnetic/color-coded micro beads.
In a preferred embodiment of the present invention, the method of detection is capillary electrophoresis. The demand from the human genome project greatly stimulated technology development in DNA sequencing and, in return, improvements in DNA sequencing greatly speeded up the human genome project. As a result, capillary DNA sequencers became widely available to researchers in both academe and industry. Capillary
DNA sequencers are highly sensitive and automated detection systems. They also have a relatively broad detection range, covering at least three orders of magnitude. Their analytical power is better than most signal detection systems currently used for SNP genotyping. Capillary DNA sequencing systems have been proven to deliver ultra high throughput in many DNA sequencing centers around the world.
Capillary electrophoresis has been used in DNA polymorphism analysis (Barta, 2001 ; Medintz 2001). Most of these studies exploited the sensitivity and speed of separation. Lindblad-Toh et al (2000) used a DNA sequencer to increase throughput. In this study, the authors chemically synthesized oligonucleotides from 18-50 bases as extension primers and succeeded in scoring 14 SNPs in one lane (The size difference between primers was 4 bases, there were a few sets of oligos of the same length but of different sequences that were used to score two different SNPs by different colors). This study essentially proved that DNA sequencers had the potential for high capacity SNP scoring using the SBE format, and the length of primers was the limiting factor for throughput.
The wide availability, high detection sensitivity, high throughput capacity and automation readiness of capillary DNA sequencers call for high capacity applications, and SNP genotyping is one of such applications. If these two are united, considerable advances in cost and throughput would be achieved. Many did not consider DNA sequencers for high throughput SNP scoring mainly because it was not cost-effective. DNA sequencers separate DNA fragments by sizes and colors. In order to separate genotyping products by a sequencer, the products must be different in sizes and or colors. To separate two SBE products, for example, SBE primers must be different in length or the extended bases must be different in color. Otherwise, the two products of same length and same colors would not be distinguished. While it is reasonable to chemically synthesize primers of 15-40 bases, this size range gives only limited multiplex capacity (Lindblad-Toh 2000) ). To chemically synthesize primers longer than 50 bases is not economical, especially in high throughput settings. But a sequencer can separate DNA fragments up to 600-800 bases. In the practice of the present invention as described above, SBE products can be arranged to be 5 bases apart for 600-800 bases, allowing the loading over 100 SBE products in one lane. Multiplexing at this level makes it reasonable to use sequencers for SNP scoring. Furthermore, practical protocols for using DNA sequencers are well-established and many handling and procedures involved have been automated and are readily available for large scale applications.
The following examples are intended to be illustrative in nature and are not intended to be limit the scope of the invention in any way. EXAMPLES Example 1. Formation of sequencible structures.
Sets of nPCR primers were designed as described to amplify DNA fragments from six markers of human chromosome 6 and individual nPCR was performed using Taq-Gold DNA polymerases. Clean-up digestion was carried out using shrimp alkaline phosphatase and E. coli exonuclease I (37 °C 1 hour) After the clean-up digestion, a high temperature denaturing (95 °C for 15 min.) was performed and the samples were allowed to cool to room temperature. A sequencing reaction was performed using standard sequencing kits but without sequencing primers. Sequencing reactions were performed either : 1) under standard cyclic sequencing program: 25 cycles of 96 °C forl min., 50 °C for 15 sec. and 60 °C for 4 min; or 2) using this condition: 25 cycles of 96 °C for 1 min., 80 °C for 4 min. The purpose of these experiments was to test whether a sequencible structure formed after denaturing and reannealing of the outer and inner PCR products together. If we obtained sequences and the sequences matched the inner PCR primer position, this would confirm that sequencible structures did form as expected.
The results from experiments with two of the six markers are shown in Figure 3 A and B and Figure 4 A and B. These figures show the results obtained with the second sequencing reaction protocol. Figures 3 A and 4A show PCR primer positions and orientations, and the expected sequences. Note that in Figure 4, the inner PCR primer is designed in the same orientation as forward, so the sequence reading from a sequencing reaction would be reverse complementary to the sequences highlighted with italics. Figures 3B and 4B show sequencing reads from the ABI 377 sequencer analysis software.
For the 6 markers tested, we obtained sequences for five, and all of these sequences matched the expected sequences exactly. Full length sequence reads (from the ends of inner PCR products to the ends of outer PCR products) were obtained when the standard cyclic sequencing conditions were used (data not shown). Much shorter sequence readings (30- 50bases) were obtained when the extension temperature was changed to 80 °C (as in Figures 3 and 4). For 4 of the 5 makers that produced sequences the sequence started right after the inner primers, one started 3 bases away from the end of the primer. For both sequencing conditions, the starting positions of sequencing were the same. Example 2. Creating sequencible structures with products from extendase-free Pfu DNA polymerases that can be used for SBE genotyping reactions
The variations of starting position of the obtained sequences (Example 1) suggested that the positioning of inner PCR primers alone may not be sufficient to obtain sequencible structures with precise extending ends. An alternative is the use of extendase-free DNA polymerases that do not add the 3 ' A base at the ends of PCR products. Thus, experiments were carried out using Pfu DNA polymerases which have been reported for lacking the extendase activity (10, 28). Inner PCR primers were designed so that their products would be positioned right before the polymorphic site if the products formed sequencible structures. Inner and outer PCR reactions were performed separately using Pfu DNA polymerases and the products wqere pooled together to form the sequencible structures. Then a SBE reaction was performed using SNaPshot kit from Applied BioSystems. SBE reactions were purified and analyzed by ABI 377 DNA sequencer using GeneScan.
Three samples were shown in Figure 5, representing three genotypes for the marker: Homozygous A/A (upper panel), heterozygous A/G (middle panel) and homozygous G/G (lower panel). The experiments demonstrated that Pfu DNA polymerases produce inner PCR products with precise ends that can be used to form sequencible structures for SBE reactions and to score genotypes correctly. In a parallel experiment using Taq DNA polymerases multiple products were observed and genotypes were not clear (data not shown). The results clearly show the differences between the two DNA polymerases. Example 3. Control of the reading length for Multiple Target Sequencing
The reading length of sequencing reactions is principally determined by the ratio of dNTPs/ddNTPs. For typical sequencing applications, long sequence reads are obtained by using a high dNTPs/ddNTPs ratio (-100:1) provided in commercial sequencing kits. In the practice of the present invention, a short stretch of DNA surrounding the SNP targets will be sequenced. For this purpose it is desirable to control the length of sequence reads so that multiple sequencing reactions can be loaded in one lane/capillary without overlapping each other. Currently there is no commercially available kit for this purpose, but two products, the SNaPShot from Applied Biosystems and the SNuPe from Amershan Biosciences, have the potential to be modified for this purpose. Both these kits were designed for SBE reactions, containing only dye-labeled ddNTPs. The concentration of nucleotides in the mix is proprietary.
Individually available dye-labeled nucleotides were used to assemble a testing kit to demonstrate the principle that reading length can be controlled by dNTPs/ddNTPs ratio. Figure 6 shows an example of the sequencing reaction. In this reaction, dye-labeled acyclo- ddNTPs were used to assemble the mix. The sequencing reaction was performed using pGEM plasmid and Ml 3 -21 primer. The ratio of dNTPs/ddNTPs and thermal cycling conditions are detailed in the figure legend. The results showed a clean read of 30-40 bases after the primer.
This example demonstrated that the reading length can be effectively controlled by the ratio of dNTPs/dDNTPs. To practice the current invention, especially the MulTarSeq, a specially formulated sequencing mix is therefore desirable. Example 4. Comparison of Two-Step PCR Amplification using Primary and Secondary Primer Sets Four SNP markers randomly were chosen from our SNP collection and PCR and nPCR primers were designed. Both outer and inner primers had two designs, a simple design and the two domain design. The sequences used for the common domains of the two domain were the Ml 3 universal forward primer: cccagtcacgacgttgtaaaacg (for forward outer PCR primers) and Ml 3 universal reverse primer: agcggataacaatttcacacagg (for reverse outer PCR primers). For the inner PCR primer the common domain sequence was tcaGCAGCatGTCTCttcca, which contains recognition sites for two restriction enzymes
(Bst71 1 and Alw261, in capital letters). Multiplex PCR and multiplex nPCR reactions were performed to compare the primer designs and protocols. PCR products were then analyzed by agarose gel electrophoresis. Figure 7 showed the results. Lane 1 of Figure 7 represents a 4x multiplex PCR using simple primer design. As ca be seen, only two bands are visible (480,510 bp). They could not be resolved by agarose gel electrophoresis. Lane 2 represents the same 4 amplicons, but generated using the two domain design. In this case, the two smaller products (400, 430 bp) are clearly seen. Note the size shifted for the larger products due to extra length (46 bp) in the two domain primers. Lane 3 represents 4x multiplex nPCR with the same amplicons but carried out by the two-step porcedure. In addition to the 4 outer PCR products, 4 inner PCR productscan also be seen.
This experiment demonstrates that the two domain design significantly improves both multiplex PCR and multiplex nPCR, and that the two-step procedure is especially effective to improve multiplex nPCR.
Example 5. Use of Multiplex nPCR to Create an Ordered Series of Sequencible
Structures This example is provided to illustrate how a series of sequencible structures are formed from two multiplexed PCRs. A set of five SNPs are selected and nPCR primers are designed using the two domain design. In order to run all products on a single sequencing lane/capillary, the inner PCR products are arranged to span 150 to 400 bps range, 50 bps apart from one another. The common domain for the inner primers should contain a restriction enzyme recognition site to produce blunt ends after the amplification. Two 5x mulitiplexing PCRs are performed separately: one uses only the outer PCR primers the other uses only the inner PCR primers. After the amplification an appropriate restriction enzyme is used to remove the common tag sequences from the inner end of the inner PCR products. The outer products and the inner products then are combined, purified, denature and reannealed together. A single base extension reaction is performed using the SNaPshot kit from Applied Biosystems. The products then are purified and run on DNA sequencer. The analysis of the extension products will identify the genotypes of the sample.
While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.
REFERENCES
Armstrong B, Stewart M, Mazumder A. 2000. Suspension arrays for high throughput, multiplexed single nucleotide polymorphism genotyping. Cytometry 40:102-8 Barta C, Ronai Z, Sasvari-Szekely M, Guttman A. 2001. Rapid single nucleotide polymorphism analysis by primer extension and capillary electrophoresis using polyvinyl pyrrolidone matrix. Electrophoresis 22:779-82
Bray MS, Boerwinkle E, Doris PA. 2001. High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum. Mutat. 17:296-304
Cai H, White PS, Torney D, Deshpande A , Wang Z, Keller RA, Marrone B, Nolan JP. 2000. Flow cytometry-based minisequencing: a new platform for high-throughput single- nucleotide polymorphism scoring. Genomics 66:135-43
Chen X, Levine L, Kwok PY. 1999. Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res. 9:492-8
Chen X, Zehnbauer B, Gnirke A, Kwok PY. 1997. Fluorescence energy transfer detection as a homogeneous DNA diagnostic method. Proc Natl. Acad. Sci. U. S. A 94:10756-61
Chen X, Livak KJ, Kwok PY. 1998. A homogeneous, ligase-mediated DNA diagnostic test. Genome Res. 8:549-56
Chen X, Kwok PY. 1997. Template-directed dye-terminator incorporation (TDI) assay: a homogeneous DNA diagnostic method based on fluorescence resonance energy transfer. Nucleic Acids Res. 25:347-53
Cline J, Braman JC, Hogrefe HH. 1996. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res. 24:3546-51
Coljee VW, Murray HL, Donahue WF, Jarrell KA. 2000. Seamless gene engineering using RNA- and DNA-overhang cloning. Nat. Biotechnol. 18:789-91 Collins FS, Guyer MS, Charkravarti A. 1997. Variations on a theme: cataloging human DNA sequence variation. Science 278:1580-1
Delahunty C, Ankener W, Deng Q, Eng J, Nickerson DA. 1996. Testing the feasibility of DNA typing for human identification by PCR and an oligonucleotide ligation assay. Am. J. Hum. Genet. 58:1239-46
Dubertret B, Calame M, Libchaber AJ. 2001. Single-mismatch detection using gold- quenched fluorescent oligonucleotides. Nat. Biotechnol. 19:365-70
Fan JB, Chen X, Halushka MK, Berno A, Huang X, Ryder T, Lipshutz RJ, Lockhart DJ, Chakravarti A. 2000. Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res. 10:853-60
Ferguson JA, Steemers FJ, Walt DR. 2000. High-density fiber-optic DNA random microsphere array. Anal. Chem. 72:5618-24
Fors L, Lieder KW, Navra SH, Kwiatkowski RW. 2000. Large-scale SΝP scoring from unamplified genomic DΝA. Pharmacogenomics. 1 :219-29
Gal J, Schnell R, Szekeres S, Kalman M. 1999. Directional cloning of native PCR products with preformed sticky ends (autosticky PCR). Mol. Gen. Genet. 260:569-73
Gal J, Schnell R, Kalman M. 2000. Polymerase dependence of autosticky polymerase chain reaction. Anal. Biochem. 282:156-8
Germer S, Holland MJ, Higuchi R. 2000. High-throughput SΝP allele-frequency determination in pooled DΝA samples by kinetic PCR. Genome Res. 10:258-66
Germer S, Higuchi R. 1999. Single-tube genotyping without oligonucleotide probes. Genome Res. 9:72-8 Gerry NP, Witowski NE, Day J, Hammer RP, Barany G, Barany F. 1999. Universal DNA microarray method for multiplex detection of low abundance point mutations. J. Mol. Biol. 292:251-62
Gilles PN, Wu DJ, Foster CB, Dillon PJ, Chanock SJ. 1999. Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips. Nat. Biotechnol. 17:365-70
Hu G. 1993. DNA polymerase-catalyzed addition of nontemplated extra nucleotides to the 3' end of a DNA fragment. DNA Cell Biol. 12:763-70
lannone MA, Taylor JD, Chen J, Li MS, Rivers P, Slentz-Kesler KA, Weiner MP. 2000. Multiplexed single nucleotide polymorphism genotyping by oligonucleotide ligation and flow cytometry. Cytometry 39: 131-40
Kruglyak L. 1999. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat. Genet. 22:139-44
Kwok PY. 2000. High-throughput genotyping assay approaches. Pharmacogenomics. 1 :95- 100
Lindblad-Toh K, Winchester E, Daly MJ, Wang DG, Hirschhorn JN, Laviolette JP, Ardlie K, Reich DE, Robinson E, Sklar P, Shah N, Thomas D, Fan JB, Gingeras T, Warrington J, Patil N, Hudson TJ, Lander ES. 2000. Large-scale discovery and genotyping of single- nucleotide polymorphisms in the mouse. Nat. Genet. 24:381-6
Lindroos K, Liljedahl U, Raitio M, Syvanen AC. 2001. Minisequencing on oligonucleotide microarrays: comparison of immobilisation chemistries. Nucleic Acids Res. 29:E69
Long AD, Langley CH. 1999. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res. 9:720-31 Marras SA, Kramer FR, Tyagi S. 1999. Multiplex detection of single-nucleotide variations using molecular beacons. Genet. Anal. 14:151-6
Medintz I, Wong WW, Berti L, Shiow L, Tom J, Scherer J, Sensabaugh G, Mathies RA. 2001. High-performance multiplex SNP analysis of three hemochromatosis- related mutations with capillary array electrophoresis microplates. Genome Res. 11 :413-21
Metzker ML, Lu J, Gibbs RA.Electrophoretically uniform fluorescent dyes for automated DNA sequencing. Science. 1996; 271(5254): 1420-2.
Myakishev MN, Khripin Y, Hu S, Hamer DH. 2001. High-throughput SΝP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res. 11 : 163-9
Nikiforov TT, Rendle RB, Goelet P, Rogers YH, Kotewicz ML, Anderson S, Trainor GL, Knapp MR. 1994. Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms. Nucleic Acids Res. 22:4167-75
Nordstrom T, Nourizad K, Ronaghi M, Nyren P. 2000. Method enabling pyrosequencing on double-stranded DNA. Anal. Biochem. 282 : 186-93
Pastinen T, Raitio M, Lindroos K, Tainola P, Peltonen L, Syvanen AC. 2000. A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res. 10:1031-42
Pastinen T, Kurg A, Metspalu A, Peltonen L, Syvanen AC. 1997. Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays. Genome Res. 7:606-14
Pastinen T, Partanen J, Syvanen AC. 1996. Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation. Clin. Chem. 42:1391-7 Perler FB, Kumar S, Kong H. 1996. Thermostable DNA polymerases. Adv. Protein Chem. 48:377-435
Prince JA, Feuk L, Howell WM, Jobs M, E ahazion T, Blennow K, Brookes AJ. 2001. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res. 11:152-62
Riley JH, Allan CJ, Lai E, Roses A. 2000. The use of single nucleotide polymorphisms in the isolation of common disease genes. Pharmacogenomics. 1:39-47
Ronaghi M. 2001. Pyrosequencing sheds light on DNA sequencing. Genome Res. 11:3-11
Ross P, Hall L, Smirnov I, Haff L. 1998. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat. Biotechnol. 16:1347-51
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ , Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Atshuler D. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-33
Sauer S, Lechner D, Berlin K, Plancon C, Heuermann A, Lehrach H, Gut IG. 2000. Full flexibility genotyping of single nucleotide polymorphisms by the GOOD assay. Nucleic Acids Res. 28:E100
Shi MM. 2001. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin. Chem. 47:164-72
Shuber AP. 1999. US Patent No. 5882856 Stump MD, Cherry JL, Weiss RB. 1999. The use of modified primers to eliminate cycle sequencing artifacts. Nucleic Acids Res. 27:4642-8
Syvanen AC. 1999. From gels to chips: "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms. Hum. Mutat. 13:1-10
Tong J, Cao W, Barany F. 1999. Biochemical properties of a high fidelity DNA ligase from Thermus species AK16D. Nucleic Acids Res. 27:788-94
Tong J, Barany F, Cao W. 2000. Ligation reaction specificities of an NAD(+)-dependent DNA ligase from the hyperthermophile Aquifex aeolicus. Nucleic Acids Res. 28:1447-54
Woolley AT, Guillemette C, Li CC, Housman DE, Lieber CM. 2000. Direct haplotyping of kilobase-size DNA using carbon nanotube probes. Nat. Biotechnol. 18:760-3
Ye F, Li MS, Taylor JD, Nguyen Q, Colton HM, Casey WM, Wagner M, Weiner MP, Chen J. 2001. Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification. Hum. Mutat. 17:305-16

Claims

CLAIMSWe claim:
1. A method of producing hybrid DNA with a single strand overhang that includes a target site, comprising the steps of: obtaining a first primer which hybridizes to a 5' strand of a strand of deoxyribonucleic acid (DNA), a second primer which hybridizes to a 3' strand of said strand of DNA, and a third primer which hydridizes to said 3' strand of DNA; producing by nested polymerase chain reaction (PCR) using said first primer, said second primer, and said third primer, an outer amplicon which includes said target site and an inner amplicon which excludes said target site; and forming at least one of a ligatable structure which includes a 3 '-5' sequence which excludes said target site hybridized to a 5 '-3' sequence which includes said target site, and a sequencible structure which includes a 5 '-3' sequence which excludes said target site hybridized to a 3'-5' sequence which includes said target site.
2. The method of claim 1 wherein said forming step forms both said ligatible structure and said sequencible structure.
3. The method of claim 1 wherein said target site includes at least one single nucleotide polymorphism.
4. A method of genotyping DNA of an individual by analyzing at least one target site in said DNA, comprising the steps of: obtaining a first primer which hybridizes to a 5' strand of a strand of said DNA, a second primer which hybridizes to a 3' strand of said strand of DNA, and a third primer which hydridizes to said 3' strand of DNA; producing by nested polymerase chain reaction (PCR) using said first primer, said second primer, and said third primer, an outer amplicon which includes said target site and an inner amplicon which excludes said target site; and forming at least one of a sequencible structure which includes a 5'-3' sequence which excludes said target site hybridized to a 3'-5' sequence which includes said target site; and a ligatable structure which includes a 3 '-5' sequence which excludes said target site hybridized to a 5'-3' sequence which includes said target site; and analyzing at least one of a sequencing product formed by sequencing said sequencible structure and a ligation product formed by ligating said ligatible structure with a labeled oligonucleotide with a DNA sequencer to determine the genotype of said individual.
5. The method of claim 4 wherein said forming step forms both said ligatible structure and said sequencible structure.
6. The method of claim 4 wherein said at least one target site includes a single nucleotide polymorphism.
7. The method of claim 4 wherein said sequencible structure is sequenced by a technique selected from the group consisting of dideoxy sequencing, pyrosequencing, and single base extension.
8. The method of claim 4 wherein a plurality of target sites are simultaneously analyzed by the step of producing an ordered series of sequencing products of varying, non-overlapping length each specific for a particular target site, and wherein said step of analyzing is carried out by electrophoresing said ordered series of sequencing products in a single channel of said DNA sequencer.
9. The method of claim 8 wherein said step of producing an ordered series of sequencing products is carried out by single base extension (SBE).
10. The method of claim 8 wherein said step of producing an ordered series of sequencing products is carried out by a dideoxy sequencing reaction utilizing a low ratio of dNTPs to ddNTPs.
11. The method of claim 4 wherein said labeled oligonucleotide is fluorescently labeled.
12. The method of claim 4 wherein a plurality of ligatable structures are formed in said forming step, each being specific for one of a plurality of target sites, and said ligation products are of varying, non-overlapping lengths with said labeled oligonucleotides being degenerate, said step of analyzing is carried out by electrophoresing a plurality of ligation products in a single channel of said DNA sequencer.
13. A method for analyzing at least one target site in a DNA molecule, comprising the steps of amplifying by nested PCR said target site , wherein said nested PCR is carried out using inner and outer PCR primer pairs, wherein said outer PCR primer pair forms a first PCR product which contains said target site, and wherein said inner PCR primer pair forms a second PCR product which contains a portion of said first PCR product but does not contain said target site , denaturing said first and said second PCR products to form ssDNA sequences, reannealing said ss DNA sequences to form a sequencible hybrid DNA molecule and a ligatible hybrid DNA molecule, performing sequencing reactions with said sequencible hybrid DNA molecule and ligation reactions with said ligatible hybrid DNA molecule, and determining the characteristics of said target site by analyzing results obtained in said performing step.
14. The method of claim 13 wherein said at least one target site is an SNP polymorphism site.
15. The method of claim 13 wherein said inner and outer primer pairs comprise a sequence tag.
16. The method of claim 15 wherein said sequence tag comprises a restriction enzyme recognition site.
17. The method of claim 13 wherein said step of amplifying is carried out using a low concentration of primers, and further comprising a second step of amplifying, wherein said second step of amplifying uses secondary primers for amplification of said sequence tags.
18. The method of claim 13 wherein one target site is analyzed.
19. The method of claim 13 wherein a plurality of target sites are analyzed.
20. The method of claim 13 wherein said step of amplifying is carried out in a single multiplex PCR reaction.
21. The method of claim 13 wherein said step of amplifying is carried out in multiple independent PCR reactions.
22. The method of claim 13 wherein said results obtained in said performing step are analyzed by a DNA sequencer.
23. Inner and outer PCR primer pairs for the amplification of a target site in a DNA molecule, wherein said outer PCR primer pair forms a first PCR product which contains said target site, and wherein said inner PCR primer pair forms a second PCR product which contains a portion of said first PCR product but does not contain said target site.
24. The primer pairs of claim 23, wherein said target site is an SNP polymorphism site.
25. The primer pairs of claim 23, wherein said primer pairs comprise a sequence tag.
26. A kit for amplification of at least one target site in a DNA molecule, comprising inner and outer PCR primer pairs for the amplification of said target site , wherein said outer primer pair amplifies a portion of said DNA molecule including said target site, and wherein said inner primer pair amplifies part of said portion of said DNA molecule amplified by said outer primer pair and excludes said target site.
27. The kit of claim 26 wherein said inner and outer PCR primer pairs comprise sequence tags.
26. The kit of claim 27, further comprising secondary primers for the amplification of said sequence tags.
27. A dideoxy DNA sequencing kit for producing short chain termination fragments, comprising dNTPs and ddNTPs present in a dNTP:ddNTP ratio ranging from 1 :0 to 1 : 10.
PCT/US2002/014431 2001-05-09 2002-05-09 Multiple sequencible and ligatible structures for genomic analysis WO2002090505A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/476,970 US7262030B2 (en) 2001-05-09 2002-05-09 Multiple sequencible and ligatible structures for genomic analysis
AU2002305436A AU2002305436A1 (en) 2001-05-09 2002-05-09 Multiple sequencible and ligatible structures for genomic analysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28951401P 2001-05-09 2001-05-09
US60/289,514 2001-05-09

Publications (2)

Publication Number Publication Date
WO2002090505A2 true WO2002090505A2 (en) 2002-11-14
WO2002090505A3 WO2002090505A3 (en) 2003-02-27

Family

ID=23111869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014431 WO2002090505A2 (en) 2001-05-09 2002-05-09 Multiple sequencible and ligatible structures for genomic analysis

Country Status (3)

Country Link
US (1) US7262030B2 (en)
AU (1) AU2002305436A1 (en)
WO (1) WO2002090505A2 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095923A1 (en) * 2006-02-20 2007-08-30 Biotype Ag Method for analysing multiplex-mixtures comprising nucleic acid amplification products having overlapping detection areas
EP2031070A1 (en) * 2002-12-04 2009-03-04 Applera Corporation Multiplex amplification of polynucleotides
WO2010125351A1 (en) * 2009-04-29 2010-11-04 The Anthony Nolan Trust Simultaneous sequencing of multiple nucleic acid sequences
US8304214B2 (en) 2000-06-06 2012-11-06 Applied Biosystems, Llc Methods for multiplexing amplification reactions
CN109415764A (en) * 2016-07-01 2019-03-01 纳特拉公司 For detecting the composition and method of nucleic acid mutation
US10711309B2 (en) 2005-11-26 2020-07-14 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US10731220B2 (en) 2010-05-18 2020-08-04 Natera, Inc. Methods for simultaneous amplification of target loci
US10774380B2 (en) 2010-05-18 2020-09-15 Natera, Inc. Methods for multiplex PCR amplification of target loci in a nucleic acid sample
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11286530B2 (en) 2010-05-18 2022-03-29 Natera, Inc. Methods for simultaneous amplification of target loci
US11306357B2 (en) 2010-05-18 2022-04-19 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11319595B2 (en) 2014-04-21 2022-05-03 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11390916B2 (en) 2014-04-21 2022-07-19 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US11519028B2 (en) 2016-12-07 2022-12-06 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
EP2359689B1 (en) 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
US7300755B1 (en) * 2003-05-12 2007-11-27 Fred Hutchinson Cancer Research Center Methods for haplotyping genomic DNA
WO2005038039A2 (en) * 2003-10-13 2005-04-28 Genaco Biomedical Products, Inc. Method for multiplex primer based amplification of nucleic acids
WO2006071568A2 (en) * 2004-12-29 2006-07-06 Applera Corporation Methods, compositions, and kits for forming labeled polynucleotides
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7544473B2 (en) 2006-01-23 2009-06-09 Population Genetics Technologies Ltd. Nucleic acid analysis using sequence tokens
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
JP2009048280A (en) * 2007-08-15 2009-03-05 Nikon Corp Mechanism analysis program
US8320704B2 (en) * 2007-09-21 2012-11-27 Gatan, Inc. Method for creating reference images in electron microscopes
CA2737643C (en) 2008-09-20 2020-10-06 Hei-Mun Fan Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2010123625A1 (en) 2009-04-24 2010-10-28 University Of Southern California Cd133 polymorphisms predict clinical outcome in patients with cancer
WO2011084757A1 (en) 2009-12-21 2011-07-14 University Of Southern California Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancer
WO2011085334A1 (en) 2010-01-11 2011-07-14 University Of Southern California Cd44 polymorphisms predict clinical outcome in patients with gastric cancer
US9222122B2 (en) 2012-11-20 2015-12-29 Src, Inc. System and method for rapid detection and identification of nucleic acid labeled tags
WO2017176896A1 (en) * 2016-04-07 2017-10-12 Illumina, Inc. Methods and systems for construction of normalized nucleic acid libraries
EP3551756A4 (en) 2016-12-12 2020-07-15 Dana Farber Cancer Institute, Inc. Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection
US11174511B2 (en) 2017-07-24 2021-11-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087485A (en) * 1998-01-21 2000-07-11 Axys Pharmaceuticals, Inc. Asthma related genes
US6228594B1 (en) * 1996-04-04 2001-05-08 Bio-Rad Laboratories, Inc. Method for determining the presence or absence of a hereditary hemochromatosis gene mutation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228594B1 (en) * 1996-04-04 2001-05-08 Bio-Rad Laboratories, Inc. Method for determining the presence or absence of a hereditary hemochromatosis gene mutation
US6087485A (en) * 1998-01-21 2000-07-11 Axys Pharmaceuticals, Inc. Asthma related genes

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815546B2 (en) 2000-06-06 2014-08-26 Applied Biosystems, Llc Methods for multiplexing amplification reactions
US10106845B2 (en) 2000-06-06 2018-10-23 Applied Biosystems, Llc Methods for multiplexing amplification reactions
US9481907B2 (en) 2000-06-06 2016-11-01 Applied Biosystems, Llc Methods for multiplexing amplification reactions
US8304214B2 (en) 2000-06-06 2012-11-06 Applied Biosystems, Llc Methods for multiplexing amplification reactions
US9206475B2 (en) 2000-06-06 2015-12-08 Applied Biosystems, Llc Methods for multiplexing amplification reactions
US9822405B2 (en) 2002-12-04 2017-11-21 Applied Biosystems, Llc Multiplex amplification of polynucleotides
US8323897B2 (en) 2002-12-04 2012-12-04 Applied Biosystems, Llc Multiplex amplification of polynucleotides
EP2031070A1 (en) * 2002-12-04 2009-03-04 Applera Corporation Multiplex amplification of polynucleotides
US11667964B2 (en) 2002-12-04 2023-06-06 Applied Biosystems, Llc Multiplex amplification of polynucleotides
US10689695B2 (en) 2002-12-04 2020-06-23 Applied Biosystems, Llc Multiplex amplification of polynucleotides
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10711309B2 (en) 2005-11-26 2020-07-14 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11306359B2 (en) 2005-11-26 2022-04-19 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
WO2007095923A1 (en) * 2006-02-20 2007-08-30 Biotype Ag Method for analysing multiplex-mixtures comprising nucleic acid amplification products having overlapping detection areas
WO2010125351A1 (en) * 2009-04-29 2010-11-04 The Anthony Nolan Trust Simultaneous sequencing of multiple nucleic acid sequences
US11312996B2 (en) 2010-05-18 2022-04-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11746376B2 (en) 2010-05-18 2023-09-05 Natera, Inc. Methods for amplification of cell-free DNA using ligated adaptors and universal and inner target-specific primers for multiplexed nested PCR
US10793912B2 (en) 2010-05-18 2020-10-06 Natera, Inc. Methods for simultaneous amplification of target loci
US10774380B2 (en) 2010-05-18 2020-09-15 Natera, Inc. Methods for multiplex PCR amplification of target loci in a nucleic acid sample
US11111545B2 (en) 2010-05-18 2021-09-07 Natera, Inc. Methods for simultaneous amplification of target loci
US11286530B2 (en) 2010-05-18 2022-03-29 Natera, Inc. Methods for simultaneous amplification of target loci
US11306357B2 (en) 2010-05-18 2022-04-19 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10731220B2 (en) 2010-05-18 2020-08-04 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11525162B2 (en) 2010-05-18 2022-12-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11519035B2 (en) 2010-05-18 2022-12-06 Natera, Inc. Methods for simultaneous amplification of target loci
US11482300B2 (en) 2010-05-18 2022-10-25 Natera, Inc. Methods for preparing a DNA fraction from a biological sample for analyzing genotypes of cell-free DNA
US11390916B2 (en) 2014-04-21 2022-07-19 Natera, Inc. Methods for simultaneous amplification of target loci
US11414709B2 (en) 2014-04-21 2022-08-16 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11408037B2 (en) 2014-04-21 2022-08-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11486008B2 (en) 2014-04-21 2022-11-01 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11371100B2 (en) 2014-04-21 2022-06-28 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11319596B2 (en) 2014-04-21 2022-05-03 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11319595B2 (en) 2014-04-21 2022-05-03 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11530454B2 (en) 2014-04-21 2022-12-20 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US11946101B2 (en) 2015-05-11 2024-04-02 Natera, Inc. Methods and compositions for determining ploidy
CN109415764A (en) * 2016-07-01 2019-03-01 纳特拉公司 For detecting the composition and method of nucleic acid mutation
EP3792365A1 (en) * 2016-07-01 2021-03-17 Natera, Inc. Compositions and methods for detection of nucleic acid mutations
EP3510171A4 (en) * 2016-07-01 2020-04-29 Natera, Inc. Compositions and methods for detection of nucleic acid mutations
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US11530442B2 (en) 2016-12-07 2022-12-20 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11519028B2 (en) 2016-12-07 2022-12-06 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA

Also Published As

Publication number Publication date
US7262030B2 (en) 2007-08-28
AU2002305436A1 (en) 2002-11-18
WO2002090505A3 (en) 2003-02-27
US20050175996A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US7262030B2 (en) Multiple sequencible and ligatible structures for genomic analysis
Kwok et al. Detection of single nucleotide polymorphisms
AU774357B2 (en) Methods of screening nucleic acids for nucleotide variations
EP1453978B9 (en) Analysis and detection of multiple target sequences using circular probes
US7014994B1 (en) Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process
US8771952B2 (en) Substances and methods for a DNA based profiling assay
US20020058250A1 (en) Extraction and utilisation of vntr alleles
Chen et al. Homogeneous genotyping assays for single nucleotide polymorphisms with fluorescence resonance energy transfer detection
WO2003020983A1 (en) Allele specific pcr for genotyping
Wittwer et al. Nucleic acid techniques
JP2003009890A (en) Polymorphic screening having high performance
EP1633888A2 (en) Means and method for the detection of target nucleotide sequences using ligation assays with improved oligonucleotide probe pairs
US20200102612A1 (en) Method for identifying the source of an amplicon
EP1520047A1 (en) Method for the characterisation of nucleic acid molecules
Zhang et al. Different applications of polymerases with and without proofreading activity in single-nucleotide polymorphism analysis
AU3893899A (en) Method for identifying nucleic acid molecules
EP1165838A2 (en) Coupled polymerase chain reaction-restriction endonuclease digestion-ligase detection reaction process
WO2006070666A1 (en) Method of simultaneously detecting gene polymorphisms
Gut An overview of genotyping and single nucleotide polymorphisms (SNP)
WO2001032929A1 (en) Methods and compositions for analysis of snps and strs
Kwitek et al. Genetic Markers and Genotyping Analyses for Genetic Disease Studies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10476970

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP